Biliary strictures in primary sclerosing cholangitis : aspects on inflammation and malignancy by von Seth, Erik
From Department of Medicine, Huddinge 
Karolinska Institutet, Stockholm, Sweden 
BILIARY STRICTURES IN 
PRIMARY SCLEROSING CHOLANGITIS  
ASPECTS ON INFLAMMATION AND 
MALIGNANCY 
Erik von Seth 
 
Stockholm 2018 
 
 Front picture by Urban Arnelo 
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Eprint  
© Erik von Seth, 2018 
ISBN 978-91-7831-048-7 
Biliary strictures in primary sclerosing cholangitis – 
aspects on inflammation and malignancy 
 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
By 
Erik von Seth 
Principal Supervisor: 
Annika Bergquist 
Karolinska Institutet 
Department of Medicine Huddinge 
Division of Gastroenterology and Rheumatology 
 
Co-supervisor(s): 
Urban Arnelo 
Karolinska Institutet 
Department of Clinical Science, Intervention and 
Technology (CLINTEC) 
Division of Surgery 
 
Stephan Haas 
Karolinska Institutet 
Department of Medicine Huddinge 
Division of Gastroenterology and Rheumatology 
 
Niklas Björkström 
Karolinska Institutet 
Department of Medicine Huddinge  
Center for Infectious Medicine  
Opponent: 
Bertus Eksteen 
University of Calgary 
Department of Medicine 
Division of Gastroenterology 
 
Examination Board: 
Marie Carlson 
Uppsala University 
Department of Medical Sciences 
Division of Gastroenterology 
 
Marianne Udd 
University of Helsinki 
Department of Surgery 
 
Jonas Halfvarson 
Örebro University 
School of Medical Sciences 
Department of Gastroenterology 
 
 

“Livet kan/får inte vara en kompromiss 
på en gång sant och falskt 
men kan inte levas utan kompromiss 
ergo sant och falskt 
  
3,99999 
är en god approximation 
för 2X2” 
Gunnar Ekelöf 
  
  
  
ABSTRACT 
Primary sclerosing cholangitis (PSC) is a rare liver disease that is characterized by chronic 
inflammation of bile ducts with development of fibrosis and strictures. The pathogenic 
mechanisms involved in this disease are insufficiently understood. PSC is associated with a 
high risk of cholangiocarcinoma (CCA), lifetime prevalence is estimated to approximately 
10%. Endoscopic retrograde cholangiopancreatography (ERCP) is a key method for 
diagnosing CCA and treating symptomatic bile duct strictures in PSC. In this thesis we have 
explored pathogenic and diagnostic aspects of biliary strictures in PSC with special focus on 
inflammation and malignancy. Specifically we aimed to evaluate (i) ERCP-related adverse 
events in PSC. (ii) Diagnostic methods for CCA in PSC. (iii) The role of mucosal associated 
invariant T-cells (MAIT cells) in PSC. 
In Paper I we investigated risk factors for ERCP-related adverse events using a nation-wide 
quality register (GallRiks). In a retrospective cohort of 8932 patients we found that the risk of 
adverse events was high in PSC patients and especially for pancreatitis and cholangitis. 
In Paper II we prospectively evaluated the feasibility, safety and diagnostic accuracy of 
single-operator cholangioscopy (SOC), a technique that allows visualization and targeted 
biopsies in the bile duct for detection of CCA. In a case-series of 47 PSC patients we showed 
that SOC could successfully be used in almost all patients (96%) and biopsies with sufficient 
material could be obtained from strictures in 95% of the cases. In a retrospective diagnostic 
study (Paper III), we evaluated the diagnostic accuracy of biliary brush cytology with 
stepwise use of fluorescence in-situ hybridization (FISH) for detection of CCA in PSC. This 
study included 208 PSC patients of whom 15 had CCA. We showed that this stepwise 
approach, with use of FISH in equivocal cytology cases, could correctly diagnose 95% of the 
patients. We also showed that sensitivity for detection CCA was higher (80%) than the 
expected using conventional cytology. 
In Paper IV we characterized circulating MAIT cells in blood in PSC and assessed their 
presence in bile ducts of PSC and non-PSC patients. We observed a reduction in levels of 
circulating MAIT cells in PSC patients compared to healthy controls, with remaining cells 
showing an activated phenotype with impaired function. These characteristics were also 
shared by patients with ulcerative colitis and primary biliary cholangitis. Using a novel 
approach to assess immune cells in bile ducts, we found MAIT cells to be specifically 
enriched within the biliary epithelium. Finally, we showed that PSC-patients had retained 
levels of MAIT cells within bile ducts. 
Taken together, our results provide insights into the clinical aspects of biliary strictures in 
PSC. We show that ERCP is associated with a high risk of procedure-related adverse events 
in PSC. Furthermore we found that SOC with targeted sampling can be utilized successfully 
in PSC. Also, that a stepwise use of FISH in biliary brush cytology has a high diagnostic 
accuracy for CCA in PSC. Finally, we give a detailed characterization of circulating MAIT 
cells in PSC and assessed their presence in the biliary epithelium. 
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1 INTRODUCTION 
1.1 GENERAL BACKGROUND 
Primary sclerosing cholangitis (PSC) is a rare liver disease that is characterized by 
inflammation of bile ducts with development of fibrosis and multifocal strictures in the 
biliary tree. A hallmark of PSC, separating it from other chronic liver diseases, is the 
association with inflammatory bowel disease (IBD), present in 60-80% of patients. Although 
first described in 1924, PSC was largely unknown until the 1970s when endoscopic 
retrograde cholangiopancreatography (ERCP) became broadly available for clinical use (1). 
In 1980, three separate publications from Norway, the UK and the US established a clinical 
definition of the disease (2-4). In the decades following, a complex clinical picture of PSC 
has emerged. Sub-phenotypes of PSC with distinct features have been identified; small-duct 
PSC, the autoimmune hepatitis overlap syndrome, and sclerosing cholangitis with high levels 
of IgG4 (5-7). The association between gastrointestinal cancer and PSC that was described 
more than three decades ago is now firmly established (8, 9). Cholangiocarcinoma (CCA) 
and colorectal cancer together constitutes 40% of all cases of PSC-related death (10). In lack 
of effective medical treatment a majority of PSC patients will progress to advanced chronic 
liver disease (11, 12). Liver transplantation (LTx) was introduced as a treatment option in the 
beginning of the 1980s and soon after, recurrent disease was described in transplanted 
patients (13, 14). Despite considerable medical advances made over the last years the main 
clinical challenges in PSC remains; there is no treatment that alters the disease course and 
there is an unpredictable risk of cancer. 
1.2 EPIDEMIOLOGY 
PSC is defined as a rare disease, affecting less than 1 per 2000 inhabitants in the EU (15). 
True incidence and prevalence is difficult to estimate, mainly because the disease lacks a 
specific ICD code (ninth and tenth revision). Pooled data from population-based studies in 
Northern Europe, Spain and North America has shown an incidence rate (IR) of 1 per 
100,000 person-years with prevalence estimated to about ten-times higher, 10 per 100,000 
persons (16). In a more recent, population-based study, covering more than 7 million 
inhabitants in the Netherlands, incidence and prevalence was 0.6 per 100,00 person-years and 
6.0 per 100,000 persons respectively (10). Geographic variations are considerable with an 
approximately 10-fold lower prevalence in Spain, Japan and Singapore compared to Northern 
Europe (17). In Sweden prevalence has been reported to 16.2 per 100,000 inhabitants (18). 
Over time incidence rates appear to be rising (16). Several mechanisms for this are plausible. 
First, the broad implementation of magnetic resonance cholangiopancreatography (MRCP), 
allowing fast, accurate and noninvasive diagnostic imaging of the biliary tree as compared to 
ERCP, is likely to have increased the detection of PSC. Second, screening with serum liver 
function tests among patients with IBD has increased in later years. This is partly explained 
by increased awareness of PSC among physicians but also because of the increased use of 
immunosuppressive therapy with hepatotoxic side effects. However, clinical features of 
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incident cases do not seem to change over time, speaking against these two detection biases 
(10). Third, the increase in PSC incidence may reflect the similar trend in IBD seen in many 
regions (19). Still, underestimation of the true incidence is likely since many PSC patients are 
asymptomatic and have normal liver function tests (20).  
1.3 CLINICAL PRESENTATION AND PHENOTYPES IN PSC 
Patients are commonly diagnosed in the third or forth decade of life, with median age 
estimated to 41 years (range 35-47), but can occur at all ages and about 10% are diagnosed in 
childhood (10, 16, 21). PSC is a predominantly male disease; approximately two thirds are 
men (55-71%). Approximately half of all of patients are asymptomatic at presentation with 
abnormal liver tests as the only indication of liver disease (11, 20, 22-26). Symptoms may 
arise either from cholestasis (e.g. right upper quadrant pain, pruritus, jaundice, bacterial 
cholangitis) or advanced chronic liver disease with portal hypertension (e.g. encephalopathy, 
variceal bleeding, ascites). A significant amount of patients, 45%-78%, will however remain 
free of symptoms despite disease progression (11, 26). 
1.3.1 IBD in PSC 
IBD is present in 60-80% of PSC patients in northern Europe and North America (10, 16, 23, 
24, 27, 28). The IBD prevalence however varies among different geographical regions, and is 
lower in for example Spanish (47%) and Japanese (34%) PSC populations (17, 29). 
Ulcerative colitis (UC) is more common than Crohn’s disease, 80% vs. 10%, and the 
remaining part present with indeterminate colitis (30). From the opposite perspective the 
prevalence of PSC in patients with UC is reported to be between 0.8% and 5.6% and 0.4% to 
6.4% in patients with Crohn’s (27, 31-34). 
Typical UC features in PSC are pancolitis with a milder course and higher risk of colorectal 
neoplasia (30) than in UC only. Patients with Crohn’s disease and PSC often have colitis 
although a small portion seems to have isolated ileal disease (10). The increased risk of 
colorectal neoplasia also affects PSC-patients with Crohn’s disease (35). 
Loftus et al first introduced the concept of a distinct IBD phenotype, PSC-IBD, in 2005 (30). 
This variant is characterized by extensive colitis with right-side predominance, backwash 
ileitis and rectal sparing. Colorectal surgery is less common in this group, but the risk of 
colorectal neoplasia higher. More recent genetic studies have shown that risk genes for PSC 
and IBD only partly overlap, supporting the theory of a separate PSC-IBD subtype (36). 
The IBD diagnosis often precedes that of PSC but can occur at any time, even after LTx (37). 
This, in combination with an often-mild course makes it difficult to exclude the diagnosis 
without a full colonoscopy with biopsies (38, 39). The correlation between IBD and PSC 
activity appears to be poor although patients with Crohn’s disease often have a milder PSC 
course and significantly better outcome (40, 41).  
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Previous epidemiological data on the relationship between PSC and IBD has been challenged 
by a Norwegian study investigating a longitudinal cohort of 322 patients with colitis (20). 
Study participants were screened with MRCP 20 years after IBD diagnosis. PSC was 
detected in 8.1% of study participants compared to 2.2% with known disease before 
screening. About two thirds of these patients had asymptomatic disease with no biochemical 
abnormalities and mild MRCP changes. Furthermore, there was no significant difference in 
prevalence of PSC between UC (6.8%) and patients with Crohn’s disease (9.0%). The long-
term prognosis of subclinical cholangiography findings are not known but this study adds to 
the notion that PSC includes a wide spectrum of disease from mild and slowly progressing to 
rapidly deteriorating with cholestatic symptoms. 
1.3.1.1 Risk of colorectal neoplasia in PSC and IBD 
The risk of colorectal neoplasia in IBD is high and correlates to disease duration, anatomic 
extent of inflammation, heredity for colorectal cancer (CRC) and concomitant PSC (42). For 
patients with UC and PSC the risk of CRC has been estimated to be about four-fold increased 
compared to UC alone (43). In case-control studies from tertiary centers the cumulative 
incidence of CRC after 10, 20 and 25 years of disease duration has been estimated to 9-14%, 
31% and 50% in PSC patients (8, 44, 45). However, data from a population-based study 
indicates that this risk is overestimated. Boonstra et al showed that the cumulative risk for 
both CRC and high-grade dysplasia of the colon was 1%, 6% and 13% after 10, 20 and 30 
years of duration in all PSC patients with IBD (10). Although less established, the high risk 
of CRC also seems to affect patients with PSC and Crohn’s disease (35, 46).  
Given the high risk of CRC current guidelines suggest a surveillance strategy with 
colonoscopy with biopsies at the time of diagnosis of PSC and subsequent yearly 
colonoscopies in patients with concomitant IBD (47).  
1.3.2 Diagnostic definitions 
PSC is a heterogenic disease grouped into different phenotypes based on clinical features. It 
is unclear whether these different variants represent separate mechanisms of disease with 
similar presentation. Main phenotypes are large-duct PSC, small-duct PSC, overlap with 
autoimmune hepatitis (AIH) and PSC with increased levels of IgG4. 
A diagnosis of PSC can be made in a patient with typical cholangiographic changes with 
exclusion of known secondary causes (secondary sclerosing cholangitis). Typical radiological 
features include irregularities and beading of intra- and extrahepatic bile ducts. The first-line 
diagnostic method is MRCP with a sensitivity and specificity of 86% and 94% respectively 
(48, 49). Evaluation with ERCP is sometimes necessary to rule out secondary causes (e.g. 
choledocholithiasis, cholangiocarcinoma) (47). Serum liver tests usually show a cholestatic 
pattern with elevated levels if alkaline phosphatase (ALP). Serum ALP however fluctuates in 
PSC and normal levels can be found even in patients with advanced cholangiographic 
changes.  
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Typical histological features of PSC include lymphocyte infiltration, bile duct proliferation, 
periportal fibrosis and ultimately loss of bile ducts (50). Diagnostic features are variably 
present and non-specific, which limits the role of liver biopsy in diagnosing large-duct PSC. 
Several autoantibodies have been evaluated for the diagnosis of PSC. Anti-nuclear (ANA), 
anti-cardiolipin and anti-smooth muscle antibodies (SMA) as well as antibodies against 
neutrophil components (ANCAs) have been associated with PSC. However, their presence 
has limited diagnostic value, as they are not disease-specific (51).  
1.3.2.1 PSC with elevated Immunoglobulin G4  
IgG4-associated cholangitis (IAC) is a variant of IgG4-related systemic disease with 
cholangiographic, biochemical and clinical features similar to PSC (52). Distinguishing 
between PSC and IAC is important since the latter may resolve with corticosteroid treatment 
and carries no known increased risk of malignancy. Patients with IAC are diagnosed using 
modified HISORt criteria (Histology, Imaging, Serology, Other organ involvement, and 
Response to steroid therapy) (52). Approximately 10% of PSC patients are reported to have 
increased levels of IgG4 without fulfilling criteria for IAC (52). It is currently unclear how 
this group relates to IAC and to what extent these patients respond to immunosuppression 
(53). However, this subgroup of PSC patients seems to have a more severe disease course, 
with shorter time to LTx (5). 
1.3.2.2 Small-duct PSC 
Patients with small-duct PSC present with a cholestatic pattern on serum liver tests and 
typical histological features but with no visible cholangiographic changes on MRCP (54). 
Prognosis is favorable compared to large-duct PSC and the risk of CCA lower but almost a 
fourth of patients will progress to the large variant within 8 years (54). 
1.3.2.3 PSC and autoimmune hepatitis 
Autoimmune hepatitis (AIH) is an immune-mediated condition affecting mainly hepatocytes 
with necroinflammation of the liver parenchyma. It is considered a classic autoimmune 
disease characterized by circulating autoantibodies (ANA, SMA), elevated levels of 
immunoglobulin G and response to immunosuppression (55). Diagnosis is based upon a 
scoring system developed in patients without other underlying liver conditions (56). Patients 
exhibiting clinical and histological features of both PSC and AIH have commonly been 
designated “PSC-AIH overlap syndrome”. The proportion of PSC-patients that exhibits such 
features has been estimated to between 7% and 14% (56). There is however no consensus on 
what constitutes an overlap syndrome and no criteria for this diagnosis exists. It has been 
suggested that these features, rather than representing a distinct disease or the presence of two 
different diseases, reflects a part of the phenotypical spectrum within PSC (56). Current 
guidelines states that each diagnosis should be considered separately and based on standard 
criteria (55). In addition, diagnostic markers are often blurred, e.g. the cholangiographic 
pattern of PSC might be mimicked by an extensive hepatic fibrosis and nodular growth in any 
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liver disease and high IgG levels might indicate AIH as well as biliary disease (55). Patients 
with PSC and features of AIH seems to benefit from immunosuppressive therapy although 
treatment response has been reported to be less pronounced (55). 
1.4 PATHOGENESIS 
The main disease mechanism in PSC is a multi-focal inflammation in large and small bile 
ducts with development of fibrosis and strictures in the biliary tree. This process is thought to 
lead to a cascade of events that results in symptomatic disease, cirrhosis and biliary neoplasia. 
Although the clinical course and complications of PSC are relatively well described, 
pathogenic factors initiating and maintaining this progressive process is poorly understood. 
Increasing evidence suggest that PSC is an immune-mediated disease were genetic and 
environmental factors contribute to the development of bile duct injury, progression and 
outcomes. Different hypothesis on main disease mechanisms has evolved over time; the 
“microbiota hypotheses”, the “gut lymphocyte homing hypothesis” and the “toxic bile 
hypothesis”. Neither of these theories is mutually exclusive to one another; nor do they fully 
explain the disease course and associated risks in PSC. 
1.4.1 Environmental factors 
Data on environmental risk factors for PSC are generally sparse with only a few published 
case-control studies (57-60). Similar to ulcerative colitis, smoking appears to be protective 
against PSC (57, 59, 60). In one case-control study the reduction in risk associated with 
smoking was confined to only PSC with concomitant IBD (58). In women, use of 
contraceptive hormones appears to be associated with a lower risk and frequent urinary tract 
infections with a higher risk (57, 58). Dietary factors may also contribute to development of 
disease and PSC patients has been found to be less likely to eat fish and grilled or barbecued 
meat (58). 
1.4.2 Genetic factors 
A genetic susceptibility was initially suggested in 1983 by studies on human leukocyte 
antigen (HLA) association among patients with PSC (61). The haplotypes HLA-B8 and 
HLA-DR3 was found in 80% of PSC patients compared to 25% in controls. More than three 
decades later, a study on risk among first degree relatives further confirmed the importance of 
genetic factors in disease etiology (62). Bergquist et al found that the risk to be diagnosed 
with PSC was increased by nearly a 4-old among first-degree relatives to patients with PSC 
(OR 3.8, 95%CI 2.1-6.8). The introduction of genome-wide association studies (GWAS) has 
further advanced the possibility of understanding the genetic risk in many so called complex 
genetic diseases, which includes PSC (63). The principle is that the genetic susceptibility for 
a disease is dependent on many variant forms of genes (risk alleles), which each contributes 
with a small increase in risk. In PSC, more than 20 different risk genes have been uncovered 
by GWAS (36, 63-70). The candidate genes with the strongest correlation to PSC are located 
within the major histocompability complex (MHC) complex on chromosome 6p21. Most 
other genes are related to inflammation and show significant overlap (pleiotropy) with other 
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immune-mediated or autoimmune conditions such as type 1 diabetes, coeliac disease and 
rheumatoid arthritis. Furthermore, there is surprisingly limited correlation between risk genes 
for PSC and IBD with only about half of the PSC genes shared by identified IBD genes. The 
strong associations with MHC together with several genes involved in T-cell function 
suggests that adaptive immunity is one key to pathogenesis in PSC. Although identified gene 
associations provide important clues to pathogenesis, it is impossible to determine exact 
mechanisms of the involved alleles (e.g. loss or gain of function) based on these data. Instead 
they offer specific opportunities to be further explored. A few examples are worth 
mentioning. Two highly pleiotropic risk loci outside the MHC region (4q27 and 10p15) 
harbors genes IL2/IL21 and IL2RA. These genes encode for IL-2 and the receptor subunit IL-
2Rα, which play an important role in both activating and inhibiting regulatory T-cells (71). 
The candidate gene CD28, encoding CD28, is involved in T-cell regulation (72). A 
significant amount of CD4 T-cells in PSC liver tissue has been shown to lack expression of 
CD28 (73). These CD28- cells locate around bile ducts and produce pro-inflammatory 
cytokines. The association of FUT2 has highlighted the role of hepatobiliary physiology and 
the interaction between host-genetics and microbiota (74). The encoded enzyme, 
fucosyltranferase-2 (FUT2) modifies glycoproteins and glycolipids by addition of fucose and, 
among other functions, serves a protective role for intestinal epithelial cells. FUT2 variants 
have been associated with altered bile microbiota and increased risk for biliary candida 
infections in PSC (75). So far, only one candidate gene, RSPO3, has been associated with 
disease prognosis (76). An important note is that the PSC-associated gene variants only 
account for 7.3% of the genetic susceptibility for PSC (77). Furthermore, although the 
relative risk of PSC in first-degree relatives is high, increase in absolute risk is very small 
given the low incidence. This underlines the possible importance of both unknown 
environmental and genetic factors in PSC. 
1.4.3 The liver as an immunological organ 
Approximately 1.5 L of blood per minute flows through the hepatic portal system. This dual 
blood supply carries both oxygenated blood from the hepatic artery and nutrient and antigen-
rich blood drained from the gut via the portal vein. The immune system of the liver must be 
able to respond to pathogens such as bacteria, viruses and parasites, and at the same time 
remain tolerant to a massive amount of dietary components and products from commensal 
bacteria. This unique property of immune tolerance is tightly regulated by a vast number of 
cells (78). 
1.4.3.1 Antigen-presenting cells 
 The liver contains multiple types of antigen-presenting cells (APCs) that together form a 
complex network that influences not only the local immunological environment but also has 
systemic effects by affecting patrolling leukocytes from the blood (79). Liver sinusoidal 
endothelial cells (LSECs) line the liver sinusoids and act as primary sensors together with 
hepatic stellate cells (HSCs). These cells can, for example, be activated by toll-like receptors 
(TLRs) and also has the capacity to present antigens to T-cells (79). However, under 
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homeostatic conditions LSECs and HSCs will not be activated by low-grade immune 
stimulation but instead induce immune tolerance by producing cytokines (i.e. IL-4, IL-10 and 
TGF-β), expressing inhibitory molecules (e.g. programmed cell death 1 ligand (PD-L1)) and 
induce regulatory T-cells through retinoic acid (78). Resident macrophages, termed Kupffer 
cells, and different subtypes of dendritic cells (DCs) also contribute to the tolerogenic milieu 
in a similar fashion under steady-state conditions. 
1.4.3.2 Lymphocytes in the liver  
The liver is particularly enriched in innate lymphoid cells (ILCs) including natural killer 
(NK) cells, which constitutes 30-50% of the total lymphocyte population (78). NK-cells play 
a critical role in the defense against viral infections and also target and kill cells that have 
undergone malignant transformation. A balance of stimulating and inhibiting factors controls 
the activation of NK cells. Stimulating factors include cytokines (e.g. IFN-α, IL-2), the Fc-
receptor for IgG and the NKG2D molecule. A major inhibitory feature of NK cells is the 
recognition of the MHC class I molecule by the killer immunoglobulin-like receptor (KIR). 
In virus-infected and tumor cells MHC class I is downregulated, and, in the presence of other 
activating signals, NK cell cytotoxicity is activated. Although ubiquitous in the liver the role 
of NK cells in autoimmune liver disease and PSC is not clear (78). The NK cell population 
has been found to be expanded in the peripheral blood of PSC-patients but not in the liver 
(80, 81). 
B cells comprise only about 6% of the total lymphocyte population in the liver and 
knowledge on their immunological function here is scarce (82). Antibody producing B cells, 
plasma cells, is present in the biliary epithelium and contributes to protection against invading 
pathogens by secreting immunoglobulin (Ig) A antibodies (83). Circulating IgA and IgG 
antibodies, reactive against biliary epithelial cells, has been reported in PSC (84).  
T-cells form the majority of lymphocytes in the human liver (82). They are adaptive immune 
cells that respond to antigen specific recognition by the T cell receptor (TCR). T cells have 
the ability to form immunological memory meaning that their response to specific pathogens 
will be qualitatively enhanced upon re-exposure. Once activated, T cells will proliferate and 
form effector cells. However, their response is dependent on co-stimulatory factors from 
other immune cells (e.g. APCs or other T cells) and these factors determine whether exposure 
to antigens will lead to activation or immune tolerance. T cells are generally divided into two 
major populations based on their functional properties and receptor expression. T helper cells 
(CD4+ TH cells) recognize antigens presented by MHC class II molecules on APCs and 
regulate the pro-inflammatory or anti-inflammatory response. Cytotoxic T cells (CD8+ T 
cells) are restricted to recognize antigens presented by MHC class I molecules and therefor 
plays a key role in the defense against virus and other intracellular pathogens. TH cells are 
further subdivided into four subsets depending on function: Regulatory T cells (TREG) 
suppress inflammation by secreting anti-inflammatory cytokines (IL-10, TGF-β) and 
consuming IL-2. TH1 cells are considered pro-inflammatory and stimulate cytotoxic T cells 
and macrophages by secretion of TNF and IFN-γ, TH2 cells activates an antibody response 
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through secretion of IL-4, IL-5, IL-10 and IL-13. TH17 cells induce activation of the innate 
immune system through IL-17 and IL-22. T cell migration to the liver is regulated by subtype 
specific interactions with chemokines. For example, the secretion of CCL17, CCL20 and 
CCL22, which interacts with the corresponding receptor CCR6, facilitates the recruitment of 
TH17 cells to the liver (85).  
T cells with TCRs that do not recognize peptides by classical MHC presentation are 
considered non-conventional T cells. Examples include γδ T cells, CD1d-restricted natural 
killer T-cells (NKT) cells and mucosal associated invariant T cells (MAIT cells). In contrast 
to the highly specific and diverse peptide recognition of the conventional TCRs these T cells 
react to broader molecular patterns of pathogens such as lipids, modified peptides and small-
molecule metabolites. They circulate and often localize in non-lymphoid tissue in abundant 
populations that show immediate effector functions upon stimulation (86). 
1.4.3.3 MAIT cells 
MAIT cells are T cells with an innate-like phenotype found in high frequencies in the 
intestinal mucosa and in the liver where they account for about 30% of all intrahepatic T cells 
(86, 87). They are characterized by the expression of a semi-invariant TCR (TCR-Vα7.2) that 
recognizes the antigen-presenting non-polymorphic MHC-like protein 1 (MR1). The antigens 
presented by MR1 are metabolites from the riboflavin and folic acid synthesis pathway in 
bacteria and fungi (88). Organisms that possess this pathway, including Enterobacter, 
Salmonella, Pseudomonas, Mycobacterium and Candida species, but not those lacking it, can 
therefore activate MAIT cells (89-91). MAIT cell expression of chemokine receptors, mainly 
CCR6 and CXCR6, and integrin-α4β7 promotes their recruitment to the liver and gut but they 
are also present in peripheral blood and lungs (87). MAIT cells express high levels of IL-18R, 
enabling activation not only through TCR signaling but also by cytokines IL-12 and IL-18 
(87). Upon activation, MAIT cells kill target cells by releasing granzyme B and perforin. 
Activation also induces rapid production of inflammatory cytokines, including IFN-γ, TNF-α, 
IL-17 and IL-22, which recruit and stimulate other immune cells. 
MAIT cells are potentially important regulators of liver and bile duct inflammation through 
some of their key features. In both healthy and diseased liver, MAIT cells predominantly 
localize around bile ducts in the portal tract (92). During inflammation, CCL20 is upregulated 
in the liver and can drive T cells expressing CCR6, including MAIT cells, to position around 
bile ducts (85). Furthermore, MAIT cells can contribute to a pro-inflammatory environment 
by the secretion of IFN-γ after activation by IL-12 and IL-18 (93). 
1.4.3.4 Breaking of tolerance 
In response to injury, pathogens and malignant cells, the homoeostatic, tolerance-inducing 
environment of the liver can be challenged and triggered to an active, inflammatory state. 
Different mechanisms, depending on type of injury or infection that initiate an inflammatory 
response have been identified (78). It is plausible that these mechanisms are shared by the 
pathological processes involved in autoimmune liver diseases. 
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Upon tissue damage or pathogen invasion, danger signals, termed alarmins, are released to 
alert the immune system (94). These molecules include pathogen-associated molecular 
patterns (PAMPs), high mobility group protein 1 (HMGB1), IL-33 and other molecules 
released from tissue, called danger-associated molecular patterns (DAMPs) (e.g free 
cholesterol, ATP). Alarmins are recognized by a vast number of cells in the liver by 
expression of pattern recognition receptors, for example nucleotide-binding oligomerization 
domain (NOD) -like receptors, scavenger receptors and TLRs (94). The APCs of the liver 
play a key role in inflammatory response. They are activated through TLRs and can also 
recognize pathogens bound to immunoglobulin or complement. Once activated they will 
induce both innate and adaptive immune cells by releasing cytokines such as TNF, IL-1β, IL-
12 and IL-18. Furthermore, recruitment of immune cells is facilitated by expression of 
chemokines and adhesion molecules (e.g. ICAM-1, VCAM-1 and E-selectin) that promote 
vascular adhesion and diapedesis (78). Parenchymal cells may also contribute to a provoked 
immune reaction. Hepatocytes, for example, induce inflammation in a fashion similar to 
APCs when exposed to bile acids that leak outside the canaliculi, as in the case of cholestatic 
disease (95). 
1.4.3.5 Cholangiocytes 
Biliary epithelial cells, cholangiocytes, line the surface of the biliary tree from the canals of 
Hering and the small intrahepatic ductules to the extrahepatic common bile duct that 
eventually drains into the duodenum (96). One of their functions is to modify bile, a mixture 
of bile salts and bile acids together with phospholipids, fatty acids, cholesterol and the 
breakdown product bilirubin, secreted by hepatocytes into the bile canaliculi (97). 
Cholangiocytes also have immunological functions. They secrete IgA into bile through a 
transport process from their basolateral side via vesicles to the apical membrane (98). 
Secreted IgA have an important physiological role in protecting the bile duct from bacteria 
ascending from the gut. Cholangiocytes are also capable of activating non-conventional T-
cells such as MAIT cells and NKT cells through MR1 and CD1d (92, 99). Moreover, they 
express pattern recognition receptors such as TLRs and can potentially act as APCs by MHC 
class II antigen presentation (100). Injured cholangiocytes will themselves initiate a series of 
events known as ductular reaction, namely proliferation, inflammatory infiltration and 
fibrosis (100). Activated cholangiocytes secrete cytokines (IL-1β, IL-6, IL-8, TGF-β, IFN-γ 
and TNF-α), chemokines and express adhesion molecules to recruit immune cells. 
Chemokines attracts pro-inflammatory TH1 and TH17 cells but also TREG cells through 
CCR10 (85, 101). Pro-fibrotic cytokines (e.g. TGF-β, MCP-1 and IL-8) released by 
cholangiocytes promotes scar formation and development of biliary fibrosis. IL-6 has, apart 
from pro-inflammatory properties, the ability to induce proliferation in cholangiocytes in an 
autocrine fashion (102). Also, chronic activation in cholangiocytes can initiate a phenomenon 
called cellular senescence (103). Cells hereby enter a permanent state of cell cycle G1 arrest 
believed to inhibit further propagation to neoplastic formation. However, senescent 
cholangiocytes can be induced to transition to pathological state called senescence-associated 
secretory phenotype (SASP), that produces pro-inflammatory cytokines and induces fibrosis 
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(104). In summary cholangiocytes are not merely passive bystanders to the events following 
bile duct injury, but actively participate in immune-regulation, tissue repair and can promote 
pathological processes. So far the mechanisms involved in this process seem to be common 
to a variety of cholangiopathic diseases and specific differences with reference to PSC 
remains to be uncovered (104).  
 
Figure 1 Histological appearance of PSC with concentric fibrosis surrounding large (left) and 
small bile ducts (right) with periductular lymphocytic infiltration. 
1.4.4 Pathophysiological processes in PSC 
1.4.4.1 Toxic bile 
Bile is essentially toxic to all living cells and cholestasis itself leads to damage of liver cells 
and inflammation in a process that can be self-sustaining and progressive (100). There is 
some evidence that the cholestatic process in PSC might have disease specific features. To 
protect themselves from the toxicity of bile cholangiocytes secrete bicarbonate that, together 
with a glycocalyx barrier, forms a so-called alkaline bicarbonate umbrella on their apical 
surface (105). Two risk genes for PSC are involved in this process, TGR5 and FUT2 (68, 70). 
TGR5 is an apical receptor on cholangiocytes that senses bile hydrophobic bile salt 
concentrations and stimulates secretion of bicarbonate and chloride (106). FUT2, described 
earlier, is thought to contribute to the formation of a stable glycocalyx (107). It has therefor 
been hypothesized that dysfunctional variants of these proteins (corresponding to the risk 
alleles) might therefore contribute to the development of biliary fibrosis in PSC. 
1.4.4.2 Gut-Liver axis and immune dysregulation 
Accumulating evidence indicate that an interaction between the immune system, 
cholangiocytes and microbes in the gut and/or bile duct might play a central role in PSC. The 
“leaky gut” hypothesis postulated that biliary inflammation is triggered by bacterial 
components entering the portal circulation through an inflamed and permeable gut (108). 
This would lead to an activation of the innate immune system through PAMP recognition and 
subsequent infiltration of lymphocytes with cholangiocytes as primary target. The role of 
intestinal microbiota in PSC has later been expanded to a “microbiota hypothesis”, taking in 
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to account that some PSC patients have no IBD or impaired intestinal permeability but 
instead may have intestinal microbial dysbiosis (meaning abnormal microbial populations in 
the gut) (109). This hypothesis combines the concepts of environmental exposure (microbial 
components) with a dysregulated cholangiocyte response to injury and is based on several 
findings. First, animal models provide evidence that microbial molecules or dysbiosis of the 
gut can trigger a PSC-like hepatobiliary inflammation (110). Second, pattern recognition 
receptors (e.g. TLRs) on cholangiocytes are upregulated in PSC (111). Third, PSC is 
associated with portal bacteremia and bile duct colonization of bacteria (112). Fourth, 
cholangiocyte cellular senescence can be induced by exposure to microbial molecules and 
cholangiocytes from PSC patients seems more prone to this transformation (113).  
Although not excluding these aforementioned mechanisms, genetic risk factors in PSC 
indicate a crucial involvement of the adaptive immune system. Circulating autoantibodies in 
combination with a strong HLA-association has led to the hypothesis that PSC is caused by 
cross-reactive immunity against antigen(s) of bacterial origin and self-antigen(s) in the gut 
and liver. This hypothesis is further supported by the fact that coexisting autoimmune 
disorders are present in up to 25% of PSC patients and that identified risk genes greatly 
overlap with other autoimmune conditions (77, 114). Circulating perinuclear ANCAs (p-
ANCAs) are frequently detected in PSC (115). These antibodies bind to the autoantigen β-
tubulin isotype 5 (TBB-5) and also cross react to the bacteria-derived protein FtsZ. This 
suggests that PSC patients have a dysregulated immune response to intestinal bacteria, but p-
ANCA is also a frequent finding in other autoimmune diseases and IBD. Hence, since 
circulating autoantibodies are not specific they might reflect sustained inflammation and 
tissue damage rather than the presence of a primary autoantigen (51). 
Other evidence for the connection between gut and liver in PSC comes from the finding of 
aberrant hepatic expression of gut-specific adhesion molecules in PSC; mucosal vascular 
addressin cell adhesion molecule 1 (MAdCAM-1); and the chemokine CCL25 (116). These 
molecules are normally expressed in gut endothelium and specifically recruit T and B cells 
expressing the integrin α4β7 (binding to MAdCAM-1) and CCR9 (the CCL25 receptor). The 
α4β7+ CCR9+ imprint on lymphocytes is made by DCs in gastric associated lymphatic tissue 
and mesenteric lymph nodes (117). Thus, T and B cells would under normal circumstances 
be imprinted by DCs and then persist as memory cells programmed to selectively target the 
gut. In PSC, the aberrant hepatic expression of MAdCAM-1 and CCL25 leads to a 
recruitment of gut-specific CD8+ T cells that can induce or sustain biliary inflammation. This 
mechanism would explain the often-independent course of IBD in PSC and the fact that PSC 
can occur even after colectomy. However, MAdCAM-1 expression in the liver is not 
confined to PSC but also found in livers affected by other types of inflammation such as AIH, 
primary biliary cholangitis (PBC) and hepatitis C (118, 119). In fact, a major confounding 
factor in the field of PSC research is that many immunological studies have been done in 
groups of patients with late stage disease (i.e. explanted livers). By the time PSC patients 
have developed biliary cirrhosis it is hard to know whether observed changes are the direct 
causing factors or secondary phenomena to cholestasis and advanced fibrosis. 
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1.5 DISEASE COURSE AND COMPLICATIONS 
The natural history of PSC is highly variable but the majority of patients will progress from 
biliary inflammation and fibrosis to cirrhosis and end-stage liver disease or CCA (10, 11, 41). 
Several, large studies has estimated median time to death or LTx to be between 9.3 to 18 
years (11, 23, 26, 44, 120-122). However, these studies have been conducted at large 
transplant centers with possible referral bias. The effect of this selection bias was 
demonstrated in a population-based study from the Netherlands (10). In 590 PSC-patients 
estimated median time to LTx or PSC-related death was much longer in the population-based 
setting, 21.3 years, compared to 13.2 years in patients derived from transplant centers. This 
corresponds to a four-fold increase in mortality compared to an age-adjusted general 
population. Nevertheless, it is highly likely that a PSC-patient, throughout a fluctuating and 
unpredictable course, will undergo a number of events with serious impact on quality of life 
and life expectancy. Before the era of LTx a majority of patients died of liver-related 
complications (123). In more recently published data the most frequent cause of death is 
reported to be CCA (32%) followed by liver failure (18%), transplant complications (9%) and 
CRC (8%) (10). The risk of other hepatobiliary malignancies in PSC, gallbladder carcinoma 
(GBC) and hepatocellular carcinoma (HCC), has less impact on mortality. Reported 
frequencies are 3.5% and 2-4% for GBC and HCC respectively (124-126).  
There is no medical treatment that affects disease course and complications in PSC although 
several drugs and combinations of drugs have been tested. LTx remains the only effective 
treatment in patients with advanced disease (49). Indications include complications of portal 
hypertension such as variceal bleeding, refractory ascites, recurrent bacterial cholangitis and 
refractory PSC-related symptoms (fatigue and pruritus) (127). Posttransplant survival is 
excellent in PSC with one and ten-year survival at 90% and 80% respectively (49). 
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Figure 2 Survival until LTx or PSC‐related death of PSC patients in the population‐based 
cohort, compared to PSC patients, referred to LTx centers (10). Printed with permission. 
1.5.1 Risk stratification 
In general, prognostic models in PSC have so far been ineffective in predicting clinical 
outcome for individual patients. The Child-Pugh score, a generic risk score in cirrhosis, 
prognosticates mortality with some precision but fails to predict disease specific 
complications (128). The revised Mayo score, a disease specific prognostic model, is the 
most widely used in the literature but was developed with a relatively short time-horizon (4 
years) and its clinical value, especially in early disease, is limited (129). The Amsterdam 
score estimates medium- and long-term prognosis using age together with cholangiographic 
changes in the intra- and extrahepatic bile ducts classified by ERCP (122). Its invasive nature 
however reduces the clinical usefulness. The use of cholangiographic changes or periductular 
enhancement seen on magnetic resonance imaging (MRI) and MRCP has so far not been 
shown to reliably predict outcome in PSC (130). Common for all prognostic models is that 
they do not include the risk of CCA. 
1.5.2 Symptomatic burden 
About 50% of patients are reported to have disease related symptoms at diagnosis and an 
additional 22% of asymptomatic patients will develop symptoms after 6 years (11, 22-24). A 
recent survey from the UK-based patient organization PSC Support indicates that this might 
be an underestimation since only 5% of patients reported no symptoms within the last 4 
weeks (131). Studies among PSC-patients on health-related quality of life are also limited by 
the fact that there are no validated disease specific quality of life measures. Most studies have 
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used generic questionnaires (e.g. the Short Form 36) or those developed for other medical 
conditions (e.g. PBC-40) (132-136). Only one study has evaluated the impact of coexisting 
IBD (137). However, PSC seems to have a significant impact on quality of life that also 
correlates to laboratory parameters (i.e. pruritus) and development of cirrhosis (133, 134). 
Refractory cholestatic symptoms such as pruritus and recurrent cholangitis can be very 
debilitating and might qualify patients for LTx in some settings (138). 
1.5.3 Biliary strictures 
The inflammation and fibrosis of bile ducts in PSC leads to the formation of intra- and 
extrahepatic biliary strictures. As the disease progress and fibrosis worsens, ductal narrowing 
occurs with impaired bile flow and ultimately obliteration of ducts. These structural changes 
in the biliary tree form the anatomic base from which cholestatic symptoms and 
complications arise in PSC. 
1.5.3.1 Visualizing the biliary tree  
Endoscopic retrograde cholangiopancreatography (ERCP) combines the use of two 
techniques, endoscopy and fluoroscopy, to visualize the biliary (and pancreatic) duct system 
(139). The first cholangiographic criteria for PSC were published in 1984, describing typical 
changes staged I-IV; from minor irregularities of duct contour to lack of filling (obliteration) 
of peripheral ducts (140). These classifications have later been elaborated on (122, 141, 142). 
The Amsterdam classification stages intra and extrahepatic cholangiographic changes that 
correlates to medium- and long-term outcomes in PSC (142). The non-invasive method of 
MRCP correlates to a high degree with ERCP findings and its main limitation is an often-
suboptimal visualization of peripheral intrahepatic ducts and the distal common bile duct 
(143, 144). Because of its comparable diagnostic accuracy, a higher cost-effectiveness and 
the risk of adverse events in ERCP (elaborated on later), current guidelines from the 
European Society for the Study of the Liver (EASL) suggest using MRCP as a first-line 
method for diagnosis (47).  
1.5.3.2 Clinical significance of biliary strictures 
Although MRCP has come to replace it as a diagnostic modality, ERCP still plays a key role 
in the management of PSC because of its ability to provide diagnostic information by bile 
duct sampling (brush cytology and biopsies) and also by its therapeutic possibilities (balloon-
dilatation and stenting of strictures) (47, 145). Treatment of biliary strictures by balloon-
dilatation, with or without stent placement, is routinely used in in other symptomatic 
cholestatic conditions such as biliary stone disease and benign strictures (146, 147). 
Furthermore, the alleviation of biliary obstruction seems to halt and possibly reverse 
cholestatic injury in other patient categories (148). However, deciding the clinical relevance 
of a stricture in PSC can be challenging. The term “dominant stricture” has come to define 
extrahepatic strictures that seem to predispose patients to clinical events (149). The exact 
definition is, somewhat arbitrary, based on stricture diameter; ≤1.5 mm in the common bile 
duct and ≤1 mm in the hepatic ducts within 2 cm of the hilum. This definition is not 
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applicable in MRCP since it is dependent on filling pressure (i.e. injection of contrast) during 
cholangiography. In addition the spatial resolution (i.e. voxel size, commonly 1x1x1 mm) in 
MRCP is insufficient for characterization of structures of that size (144, 150). Dominant 
strictures frequently occur in PSC. They are present at diagnosis in approximately 12-20% of 
patients and multiple dominant strictures may occur at the same time (24, 151, 152). In a 
cohort of 171 PSC patients at a tertiary center, 20 (12%) patients had a dominant stricture at 
diagnosis and an additional 77 (45%) patients developed strictures over a median follow-up 
of 6.9 years (152). Notably, cholestatic symptoms or associated jaundice is not part of the 
definition of the dominant stricture and there is somewhat conflicting evidence regarding its 
correlation to patient outcome. One study by Bjornsson et al retrospectively analyzed 
characteristics and outcome in PSC patients referred to ERCP (151). Out of 125 patients, 
45% had a dominant stricture. However, mean values for cholestatic serum markers ALP and 
bilirubin did not differ between these two groups at baseline. More importantly, values were 
comparable over time up to 12 months after ERCP. Although this indicates that dominant 
strictures are not necessarily associated with worsening of cholestasis at short-term follow-
up, their presence seem to predict a worse outcome in the long-term perspective even when 
excluding strictures caused by CCA. A study by Rudolph et al compared transplant-free 
survival in 171 PSC patients with and without dominant strictures (153). After 18 years of 
follow up, the stricture group had a transplant-free survival rate of 25% compared to 73% in 
the group without a dominant stricture. In summary, cholestatic symptoms and progression of 
PSC can occur both in patients with extrahepatic (i.e. dominant) strictures and in patients 
with intrahepatic strictures. The unfavorable long-term outcome associated with the presence 
of a dominant stricture might be causational but also, hypothetically, possibly caused by the 
association with a more aggressive disease phenotype.  
1.5.3.3 Treatment of biliary strictures 
Notably, almost all studies evaluating endoscopic treatment of biliary strictures in PSC are 
relatively small retrospective single-center patient-series and no study has compared 
treatment versus no treatment for dominant strictures (149, 152, 154-158). Apart from 
improved cholestatic symptoms and liver biochemistry following dilatation of dominant 
strictures, studies report decreased hospitalization rate and longer transplant-free survival 
than predicted by the Mayo risk-score. One study has evaluated the treatment of dominant 
strictures in a prospective cohort of 171 PSC patients (152). In patients treated with 
endoscopic therapy (n=96), liver biochemistry (ALP and bilirubin) as well as pruritus 
improved two weeks after dilatation. Transplant-free survival after the first dilatation in 
patients with was 81% and 52% at 5 years and 10 years respectively.  
Two different approaches are used in endoscopic treatment; balloon dilatation or insertion of 
a plastic stent (47, 145). In general, most published data concern the use of balloon dilatation 
as treatment strategy although many studies present a mix of both interventions. The use of 
short-term stenting (1-2 weeks) has been reported to be efficient in improving symptoms and 
liver biochemistry in smaller studies (157, 158). Only one retrospective study has compared 
 16 
the use of balloon dilatation versus stenting in PSC (155). Although both groups showed a 
similar response in decreased bilirubin, there were more complications (54% vs.15%) and re-
interventions (5.0 vs. 2.1) in the stent group. However, stented patients were more likely 
treated with percutaneous access (63% vs. 0%), representing a selection of patients with more 
severe strictures, and median duration of stent treatment was 3 months, increasing the risk of 
clogging and cholangitis. This limits the ability to draw conclusions on differences between 
the different treatment approaches. A multi-center randomized trial (DILSTENT), comparing 
balloon dilatation with short-term stent treatment has recently been stopped after an interim 
analysis (159). Preliminary data showed no differences in treatment effect but significantly 
more procedure related adverse events in the stent group.  
Although endoscopic intervention might seem like a rational, mechanistic approach to 
improve both short- and long-term outcomes, the quality of evidence for treatment of 
strictures can be criticized. The main limitations of these studies include retrospective design, 
the lack of control group and the choice of endpoints. Cholestatic serum markers fluctuate 
during the disease course in PSC, illustrated by the previously mentioned study on dominant 
strictures by Bjornsson et al (151). Furthermore, the Mayo risk-score was not developed to 
evaluate stricture treatment and includes bilirubin as factor. Short-term improvement by 
cholestatic markers and Mayo risk-score might therefore be explained, at least in part, by 
regression towards the mean. 
1.5.3.4 Adverse events following ERCP 
Procedure related adverse events in ERCP are categorized according to consensus criteria and 
include bleeding, perforation, infection (cholangitis) and pancreatitis (160). The total rate of 
ERCP-attributable events in a wide range of patient categories has been estimated to 6.85% 
and the mortality risk to 0.33% in a systematic review of prospective studies (161). The most 
common complication is post-ERCP pancreatitis (PEP) (3.47%), followed by infection 
(1.44%), bleeding (1.43%) and perforation (0.60%). Several risk factors, procedure- and 
patient-related, for adverse events have been identified (162-165). For example, risk factors 
for PEP include younger age, female sex and cannulation difficulties, (165). Whereas 
increased risk of bleeding is predicted by coagulopathy and sphincterotomy (162). A majority 
of studies report higher frequencies of adverse events in PSC, 7-13%, than for other 
indications (166-170). One reason for this is the increased risk of cholangitis due to the 
multiple strictures that impair bile flow and precipitate bacterial colonization and infection 
(166). Cannulation difficulties related to anatomic alterations (retracted papilla and 
hypertrophy of the right liver lobe) have also been suggested to influence the risk of PEP in 
PSC. 
1.5.4 Cholangiocarcinoma 
1.5.4.1 General background 
CCA is a malignant transformation of the intra- or extrahepatic biliary epithelium. It is a rare 
form of cancer mainly characterized by its late diagnosis and often poor prognosis. CCA is 
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commonly classified according to anatomical location; intrahepatic (iCCA) tumors are 
located proximal to the left and right hepatic bile duct (171). Extrahepatic (eCCA) tumors are 
further subdivided into hilar and distal CCA. Incidence rates of both iCCA and eCCA vary in 
different geographic regions, assumed to reflect distribution of genetic and environmental 
risk factors (172). In Denmark, for example, estimated incidence of iCCA and eCCA is 0.46 
and 0.74 per 100,00 person-years respectively (173). Surgery and LTx offers curative 
treatment but diagnosis is often made in late stages of disease with only about a third of 
patients available for such interventions (174). 
1.5.4.2 CCA in PSC 
The cumulative risk of CCA in PSC ranges from 7 to 13% in several large studies (10, 11, 
121, 175-178). The variation in risk likely reflects differences in selection of patients 
(population-based vs. tertiary center), method of case ascertainment and follow-up time. In a 
large, multi-center study from the International PSC Study Group, including 7121 PSC 
patients, 721 (10.1%) patients developed a hepatobiliary malignancy during follow-up, of 
which 594 (8.3%) had CCA (41). This risk is comparable to the results from the population-
based study by Boonstra et al, in which the cumulative risk of CCA was 6.9% (10). 
Approximately 30% to 50% of all CCAs are detected within the first year from PSC 
diagnosis (41, 121, 175). Thereafter, yearly incidence has been reported to 0.5-1.5% (41, 175-
177). Tumors can present both as iCCA and eCCA and a majority of tumors are of hilar 
origin (179). A diagnosis of CCA in PSC has generally been considered a contraindication 
for LTx. In PSC patients with CCA diagnosed both prior to and incidentally at LTx the 5-
year survival was 32% in a study fron the Nordic transplant registry (180). More recently, 
LTx with neoadjuvant therapy has been introduced as a curative treatment option in highly 
selected, early-stage cases of unresectable perihilar CCA (181). The reported 5-year 
(recurrence-free) survival is 65% in this group. Surgical resection is an option for patients 
without portal hypertension with a 5-year survival of 22-35% for patients with R0-resection 
(182).  
 
 
Figure 3 Cumulative transplant-free survival in 7121 PSC patients (A) and incidence of 
hepatobiliary malignancy (B) (41) Printed with permission 
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1.5.4.3 Pathogenesis and risk factors for CCA in PSC 
Although the pathological mechanisms leading to development of CCA in PSC are poorly 
understood, the high risk of biliary tract cancer in PSC is shared by a wide spectrum of 
diseases causing bile duct inflammation and cholestasis (172). Several studies have tried to 
identify predisposing factors and detect subgroups of PSC patients with greater risk of CCA. 
Interestingly, disease duration and development of cirrhosis in PSC does not seem to 
correlate with increased risk of CCA (176, 183, 184). Identified risk factors such as high age, 
Mayo risk-score > 4, variceal bleeding, presence of colorectal neoplasia, long duration of 
IBD and smoking only contribute to a small increase in disease liability and are not helpful in 
predicting cancer risk in a clinical setting (179). Data on genetic risk factors of CCA in PSC 
is scarce. A few risk genes for PSC (e.g. MST1, BCL2L11 and CTLA4) are suggested to also 
have impact on the carcinogenesis in CCA (104). Furthermore, two alleles of the gene 
NKG2D have been associated with lower risk of PSC-CCA (185). The NKG2D receptor has 
a crucial role in the activation of NK-cells and subsets of T-cells, suggesting that impaired 
immune-surveillance of cells with malignant transformation might play a role in tumor 
development. Another mechanism that possibly influences the transformation of 
cholangiocytes to PSC-CCA is accumulation of bile acids. Bile acids have been shown to 
induce pro-carcinogenic pathways in cholangiocytes mainly by activation of the epidermal 
growth factor receptor (EGFR) (104). 
Despite the lack of knowledge on the exact mechanisms of carcinogenesis in PSC, data 
supports the development of CCA in a sequential progression from low-grade dysplasia to 
high-grade dysplasia and ultimately invasive malignancy (186, 187). 
1.5.4.4 Diagnosing CCA in PSC 
The main difficulties of diagnosing early stages of CCA in PSC are both related to that 
disease deterioration alone can be similar to tumor development and that early stage CCA is 
often asymptomatic (188). Diagnosing early CCA often relies on a multi-modal approach 
including the use of tumor serum marker carbohydrate antigen 19-9 (CA 19-9), imaging and 
ERCP with sampling from suspicious strictures. 
CA 19-9 is a commonly used biomarker for CCA but lacks diagnostic performance in PSC 
since elevated levels often are associated with bacterial cholangitis and cholestasis and low 
levels may be observed even in the presence of advanced tumors (189). A combination of CA 
19-9 and MRI/MRCP has been suggested to increase sensitivity compared to MRI/MRCP 
alone (188). However, the low specificity of CA 19-9 reduces the diagnostic accuracy of this 
combination compared to only MRI/MRCP. 
Imaging plays a key role in assessing biliary strictures and intrahepatic lesions in PSC but 
generally lack the ability to differentiate between benign and early malignant strictures (188). 
A well-defined mass, with distinct imaging features, visible using MRI/MRCP, computed 
tomography (CT) or ultrasound (US) is highly predictive of CCA (positive predictive value 
of 100%) (188). However, such definite features of CCA on imaging are rare and sensitivity 
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is only 10-44% using this definition (188). Using MRI/MRCP to detect a combination of 
definite features of CCA and secondary signs of tumor obstruction and infiltration has the 
highest diagnostic accuracy (sensitivity of 89% and specificity of 75%) (188). 
1.5.4.5 Biliary duct sampling 
Invasive procedures such as ERCP offer the possibility to directly access the bile ducts for 
cytological and histological sampling of suspicious strictures. The purpose of this is not only 
to obtain malignant cells from CCA but also to detect biliary dysplasia that provides 
information on future risk of CCA. 
Cytological specimens from biliary duct brushing are commonly classified into different 
categories; normal (or benign), equivocal, and positive for adenocarcinoma (CCA) (190). 
Equivocal specimens can be further subdivided into atypical or atypical with suspicion of 
malignancy, which, to some extent, corresponds to the presence of low-grade (LGD) and 
high-grade dysplasia (HGD) in the biliary epithelium (191). The main strength of biliary 
brush cytology is that it is highly specific when interpreted as positive for malignancy (192). 
However, the interpretation of results in PSC is limited by several factors. First, cytology 
results are often false negative due to difficulties obtaining adequate cellular material. This is 
partly explained by an often desmoplastic growth pattern in CCA with depositions of fibrotic 
tissue around the tumor (191). Second, inter-observer variability for cytological 
categorization is high (Kappa coefficient, 0.59-0.66) (193, 194). Third, PSC is associated 
with conditions that affect the biliary epithelium and may mimic cellular atypia; biliary 
inflammation, bacterial cholangitis and prior instrumentation (195). The diagnostic 
performance of biliary brush cytology in PSC has been evaluated in a meta-analysis of 11 
studies, including 747 patients (192). The pooled diagnostic values for detecting CCA were: 
sensitivity 43%, specificity 97%, positive predictive value (PPV) 78.2% and negative 
predictive value (NPV) 87.2%. Furthermore, the correlation between cellular atypia (w/o 
suspicion of malignancy) and presence or later development of CCA is not firmly established. 
In a study including 102 PSC patients with equivocal cytology results 30 (29%) was 
diagnosed with CCA within 2 years (196). 
In order to enhance the diagnostic performance of biliary brush cytology assessment of 
chromosomal abnormalities has been introduced. Chromosomal abnormalities are manifest in 
up to 80% of biliary malignancies (197). Fluorescence in-situ hybridization (FISH) is a 
technique using DNA probes to detect loss or gain of chromosomes or chromosomal loci. In 
biliary malignancy a probe set to detect chromosomes 3, 7 and 17 and a locus-specific probe 
targeting 9p21 is the most widely used (198). Results are commonly categorized into trisomy, 
tetrasomy and polysomy. The diagnostic accuracy of FISH polysomy has been shown to be 
superior to other categories in a prospective study of 235 PSC patients with sensitivity, 
specificity, PPV and NPV of 46%, 88%, 55% and 84% respectively (199). In a meta-analysis 
including 6 studies and 690 PSC patients evaluated with FISH for polysomy, pooled results 
for sensitivity and specificity was 51% and 93% respectively (200). Two studies have also 
shown a strong association between FISH polysomy in serial or multifocal samplings and 
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development of CCA during long-term follow-up (201, 202). Furthermore, the use of FISH is 
suggested to be of higher value in the case of equivocal cytology results (196). In summary, 
detection of chromosomal abnormalities using FISH can increase sensitivity for CCA and 
identify PSC patients at greater risk for developing CCA but lacks specificity and its role in 
clinical use is not clear. 
Peroral cholangioscopy is a method for visualizing bile ducts during ERCP and allows for 
visual characterization and targeted biopsies of suspected lesions (203). Conventional peroral 
cholangioscopy has disadvantages mainly related to that it requires two endoscopists for 
maneuvering. More recently, single-operator cholangioscopy (SOC) has been introduced for 
treatment of bile duct stones and assessment of strictures (204-206). Although this technique 
has demonstrated a high success rate for visualizing strictures and targeted sampling the 
utility of SOC in PSC has only been evaluated in a few patients (206).  
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2 AIMS 
The general aim of this thesis was to explore pathogenic and diagnostic aspects of 
biliary strictures in primary sclerosing cholangitis with special focus on inflammation 
and malignancy. 
Our specific aims were: 
1. To evaluate the risk of adverse events in PSC patients undergoing ERCP (Paper I) 
2. To evaluate PSC as a risk factor for procedure-related adverse events and specifically 
post-ERCP pancreatitis (Paper I) 
3. To evaluate the feasibility, clinical utility and diagnostic accuracy of single-operator 
cholangioscopy with targeted sampling of biliary strictures in PSC (Paper II)  
4. To evaluate the diagnostic accuracy of an algorithm for biliary brush cytology with 
sequential use of FISH in equivocal cases in patients with PSC (Paper III) 
5. To describe the phenotype and function of MAIT cells in peripheral blood of PSC 
(Paper IV) 
6. To establish a method for assessing MAIT cells in the biliary epithelium of PSC 
patients and control patients (Paper IV) 
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3 MATERIALS AND METHODS 
The four studies included in this thesis are based on four different study cohorts. These 
cohorts have been generated using different methods, yet the study populations are partly 
overlapping. An overview of the study cohorts and generated papers is presented in Figure 4. 
 
Figure 4 Cohorts and generated papers in this thesis 
3.1 ETHICAL CONSIDERATIONS 
All studies have ethical approval from the regional ethics committee of Stockholm County; 
dnr 2010/2105-31/2 (Paper I); dnr 2008/1588-32 (Paper II); dnr 2015/1963-31 (Paper III); dnr 
2013/2285-31/3 and 2013/2084-31/2 (Paper IV). In studies that included prospective 
inclusion of patients (Paper II and IV), written consent was obtained from all participants. 
3.2 PAPER I 
3.2.1 Study population 
The study population was identified using the Swedish Registry for Gallstone Surgery and 
ERCP (GallRiks), a web-based nationwide quality registry. Details concerning registration 
and validation of data have previously been described (207). Between 1st of January 2007 and 
31st of December 2009 we identified 14 252 procedures in 11 316 patients at 51 ERCP 
centers. Only the first procedure for each patient during the study period was considered to 
avoid selection bias. We excluded patients younger than 18 years and used registered 
indications for ERCP to further restrict the study cohort to patients who underwent ERCP 
with the intention to diagnose and treat biliary disease. Moreover, we excluded patients with 
the indications acute pancreatitis and cholangitis as these conditions might overlap with 
evaluated adverse events. The final study cohort included 8932 patients of whom 141 had 
PSC. Patient selection and indications for ERCP are described in Figure 5. When risk for the 
2007 2017 
Paper I Paper III Paper II Paper IV 
GallRiks	
n=8932	
SOC	
n=47	
Brush	cytology	
n=208	
MAIT	
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adverse event cholangitis was calculated we excluded patients with ongoing treatment with 
antibiotics to avoid selection bias. For this analysis the cohort consisted of 7825 patients. 
3.2.2 Definitions 
Patients with PSC were defined according to the registered indication for ERCP; “PSC or 
suspicion of PSC”. We further validated that this indication represented an actual diagnosis of 
PSC by retrieving medical records for all patients who underwent ERCP at Karolinska 
University Hospital in 2009 for cross-referencing. In 30 of 34 (88%) cases the diagnosis of 
PSC could be confirmed, which we considered acceptable. 
Adverse events in GallRiks are categorized as intra-procedural or post-procedural. The 
endoscopist registers intra-procedural events in conjunction with the procedure. Appointed 
coordinators register post-procedural adverse events during a 30-day follow-up. Intra-
procedural adverse events are bleeding and extravasation of contrast. An intra-procedural 
bleeding is defined as requiring intervention such as operation or transfusion. If the bleeding 
is controlled during the procedure, through for example diathermia, it is not registered. 
Extravasation of contrast is defined as contrast leak during the procedure. Post-procedural 
events include bleeding, cholangitis, pancreatitis and perforation. Bleeding is defined in 
patients with confirmed evidence of bleeding that requires transfusion and/or endoscopic or 
other re-interventions. Cholangitis is defined as a clinical diagnosis requiring hospitalization 
for intravenous antibiotics. Consensus criteria are used to define PEP (160). Perforation is 
registered in patients with bowel or bile duct perforations. Adverse events registered in 
GallRiks are not graded by severity. 
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Figure 5 Flowchart illustrating the selection of the patient cohort from GallRiks 2007–2009. 
Printed with permission. 
3.2.3 Statistics 
Differences between groups were calculated using unpaired 2-tailed student t-test, χ2 test and 
Fischer exact test as appropriate. Backward stepwise logistic regression was used to fit a 
model for four categories of adverse events: PEP, cholangitis, extravasation of contrast and 
adverse events overall. The limited number of endpoints for the adverse events bleeding and 
perforation precluded the use of multivariate analysis in these categories. To select variables 
entered into the model, a list of explanatory values was compiled based on risk factors from 
previously published prospective studies (162-165, 208). To further select variables of 
importance we performed an initial univariate analysis for each of the categories of adverse 
events. The discriminating ability of the final predictive models selected by backward 
stepwise logistic regression was assessed using receiver-operating curves (ROCs). An area 
under the curve (AUROC) greater than or equal to 0.7 was considered as acceptable 
discrimination ability. Models were also assessed using goodness-of fit (Hosmer and 
Lemeshow test). Risk estimates are reported as Odds Ratios (ORs) and adjusted ORs (aORs). 
 
 
Indications for ERCP in 8932 patients Number % 
Common bile duct stone 3365 37.7 
Malignancy 1384 15.5 
Obstructive jaundice 3651 40.9 
Stent dysfunction 190 2.1 
Primary sclerosing cholangitis 141 1.6 
Suspected bile leakage 116 1.3 
Secondary profylaxis after previous 
gallstone pancreatits 
 
85 
 
1.0 
14 252 ERCP procedures 
10 965 ERCP procedures 
10 925 ERCP procedures 
Indications excluded 
Patients <18 years excluded 
Only first procedure considered 
- Chronic pancreatitis (n=230) 
- “Other” (n=857) 
- Acute pancreatitis (n=842) 
- Cholangitis (n=1358) 
40 procedures 
2033 procedures 
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The variables age and time were analyzed as a categorical variables. Based on previous 
studies comparing risk between precut and conventional sphincterotomy these variables were 
grouped together to increase power (166, 209). P-values less than 0.05 were considered 
significant. Analyses were carried out using SAS© System 9.1 (SAS Institute Inc., Cary, NC, 
USA) and STATISTICA 10.0 (Stat-soft®, Inc. Tulsa, OK, USA). 
3.3 PAPER II 
3.3.1 Study population 
Paper II is a prospective single-center evaluation of the feasibility, safety and diagnostic 
accuracy of SOC with targeted sampling. The study was registered with ClinicalTrials.gov 
(NCT01556555) and approved by regional ethical committee in Stockholm County 
(2008/1588-32). Informed consent was signed by all participating patients. 
Between September 2008 and May 2011 we prospectively enrolled patients with a diagnosis 
or suspicion of PSC referred to Karolinska University Hospital for ERCP. Clinical 
indications for ERCP in PSC patients at Karolinska University Hospital during the study 
period were (1) treatment of symptomatic bile duct strictures and (2) bile duct strictures with 
suspicion of malignancy, in adherence with the 2009 EASL guidelines (49). Exclusion 
criteria included; age <18 years, previous LTx and inability to provide informed consent. A 
total of 48 patients were included in the study and investigated with SOC (Spyglass direct 
visualization system, Boston Scientific Corp). One patient was diagnosed with secondary 
sclerosing cholangitis due to gall stone disease and excluded from the final analysis. A 
diagnosis of PSC was confirmed in the remaining 47 patients with cholangiographic changes 
demonstrated by MRCP and/or ERCP and exclusion of secondary causes. Patient enrollment 
and inclusion are illustrated in Figure 6. 
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Figure 6 Flowchart illustrating patient inclusion and outcomes  
3.3.2 ERCP procedure and SOC setting 
All procedures were performed in general anesthesia. Antibiotic prophylaxis with four doses 
of piperacillin/tazobactam was administered at 8-hour intervals starting immediately before 
the ERCP in all patients. Patients were observed in hospital during at least an overnight stay. 
The Olympus duodenoscope (TJF160R or TJF160VR) together with the standard Spyglass 
direct visualization system (Boston Scientific Corp.) was used in all procedures. Sampling for 
biliary brush cytology and flow cytometry was routinely performed (210). The study protocol 
did not define criteria for which sampling method to use for evaluated strictures. Whenever 
visual findings were suspicious of dysplasia or malignancy guided biopsies by mini-forceps 
(Spybite; Boston Scientific Corp.) were taken at the discretion of the endoscopist. Focal 
lesions and strictures were categorized according to macroscopic features as normal, 
suspicious or malignant. Malignancy was defined as a focal lesion with mosaic-like 
asymmetric fibrotic areas, irregular red spots as a sign of neovascularization with bleeding-
prone lesions with or without a papillar/polypoid. The study protocol did not include criteria 
for macroscopic inflammatory or postinflammatory changes of the bile duct mucosa. 
3.3.3 Data collection 
Clinical data registered included indication for ERCP, disease duration of PSC, IBD-
phenotype and duration and serum liver function tests. During ERCP with SOC, the 
procedure was documented by multiple endoscopic and radiologic images. In conjunction 
with the procedure, data were collected in a structured questionnaire completed by the 
endoscopist. Information registered included Majoie Score (141), macroscopic features of the 
bile ducts at cholangioscopy, technical difficulties, quality of the procedure, and an overall 
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judgment of whether any abnormalities observed were benign or malignant. Patients were 
followed up until death, LTx, liver resection or until the study ended in March 2014. Clinical 
routine at our institution for PSC patients with suspicious strictures is to obtain liver function 
tests, and CA 19-9 at least every 6 months. Abdominal imaging by MRCP/MR or, if 
contraindicated, ultrasound is done annually.  
3.3.4 Definitions and study outcomes 
Criteria for suspicion of malignancy on MRCP included rapid progression of a stricture, 
markedly reduced contrast excretion in the segment proximal to the stricture and thickened 
bile duct wall on contrast-enhanced images. Conventional cytology specimens were 
evaluated by a cytopathologist and categorized as follows: inadequate cellularity, normal, 
reactive, atypical, suspicious for malignancy and positive for malignancy. Biopsy specimens 
where evaluated and categorized as: inadequate, normal, reactive, low-grade dysplasia, high-
grade dysplasia and positive for adenocarcinoma.  
To evaluate the feasibility, safety and diagnostic accuracy of SOC with targeted sampling we 
defined outcomes as procedure technical success, adverse events, sampling adequacy and 
diagnostic accuracy of sampling. A procedure technical success was defined when all the 
following criteria where met: (1) advancement of the cholangioscope to the targeted stricture, 
(2) adequate endoscopic visualization of the stricture and (3) sampling of the stricture by 
brush cytology or biopsy. Adverse events were defined and graded according to the 2010 
consensus criteria of the American Society for Gastrointestinal Endoscopy (211). Diagnostic 
accuracy was defined as the accuracy of SOC-guided sampling (biopsy and/or brush 
cytology). For the purpose of this analysis all tissue samples categorized as reactive, atypical 
or suspicious of cancer were considered negative. The definite diagnosis was determined at 
the end of the follow-up period as: (1) Malignancy (CCA) defined as tissue pathology with 
evidence for adenocarcinoma. (2) Cancer-free, in patients with no evidence for cancer in 
tissue pathology from liver resection or LTx or by clinical course and imaging with no 
evidence of cancer. In addition to these outcomes we further defined the outcome additional 
technical value. This outcome was defined in patients where cholangioscopic guidance was 
used for advancement of the investigation to the targeted stricture. 
3.3.5 Statistics 
Descriptive statistics are presented as frequencies, median values and range. Analyses for 
diagnostic accuracy were done for procedures where technical success was achieved. The 
binomial exact method was used to obtain confidence interval for sensitivity, specificity, PPV 
and NPV. All analyses were carried out using STATA 13.1, StataCorp LP, College Station, 
TX, USA. 
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3.4 PAPER III 
3.4.1 Study population 
Paper III is a retrospective diagnostic study. We identified all patients with a diagnosis of 
large duct PSC who underwent ERCP with biliary brushings for cytology at Karolinska 
University Hospital between 1st January 2009 and 31st December 2015. Patients were 
identified through the pathology and cytology database, using topographic search terms for 
biliary brush cytology. This cohort was further linked to medical records to identify patients 
with PSC. All patients with a confirmed diagnosis of PSC and cholangiographic changes 
demonstrated by MRCP and/or ERCP (e.g. multifocal intra- and/or extrahepatic strictures, 
beading or narrowing of bile ducts) were included (49). Patients who had previously 
undergone LTx were excluded. The clinical indications for ERCP in PSC patients during that 
time at Karolinska University Hospital were (1) treatment of symptomatic bile duct strictures 
and (2) bile duct strictures with suspicion of malignancy in adherence with the 2009 EASL 
guidelines (49). 
3.4.2 Data collection and definitions 
Baseline clinical data (age, sex, duration of PSC, presence and duration of IBD) at the first 
(index) cytological brushing were retrieved from the electronic medical record system. Liver 
function tests up to 30 days prior to the index brushing and CA 19-9 +/- 30 days were 
recorded. Results of imaging features of MRI/MRCP within 4 months before the ERCP were 
categorized according to the original radiological reports as: (1) “Definite biliary 
malignancy”, when imaging revealed mass lesions consistent with CCA; (2) “Suspicion of 
malignancy”, when imaging demonstrated progressions of stricture(s), secondary signs of bile 
duct obstruction including reduced contrast excretion in the segment proximal of the stricture, 
and thickened bile duct wall on contrast-enhanced images and (3) “No suspicion of 
malignancy”, when none of the above criteria were fulfilled. The indication for ERCP was 
defined as: (1) “Malignancy”, when imaging results (CT or MRI/MRCP) revealed findings 
consistent with CCA; (2) Cholestatic symptoms (e.g. cholangitis, jaundice, pruritus) and (3) 
“Suspicion of malignancy”, when cholestatic symptoms or definite signs of malignancy on 
imaging were not present.  
3.4.3 Brush Cytology and Fluorescence in Situ Hybridization 
A stepwise procedure for the use of FISH in biliary brush cytology has been fully 
implemented since the 1st of January 2009 at Karolinska University Hospital. In short, brush 
cytology samples are categorized as benign (normal or reactive), equivocal (atypical or 
suspicious for malignancy) and malignant. Equivocal cases are analysed with FISH. Criteria 
for cytology and FISH are described below and the diagnostic algorithm is summarized in 
Figure 7. 
Brush samples were collected in PreserveCyt® fixative (ThinPrep®, Hologic Inc.) and cells 
were transferred to glass slides using ThinPrep 5000. Following routine staining according to 
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Papanicolaou, the following alterations were registered: (1) Architectonic atypia; (2) Nuclear 
crowding/high n:c ratio; (3) Dissociation of atypical cells; (4) Hypercromasia and nuclear 
polymorphism; (5) Atypical nuclear membranes/envelopes; (6) Atypical nucleoli (shape and 
number); (7) Coarsely granular chromatin (“salt and pepper”). Based on the number of 
present criteria the samples were categorized as follows: inadequate cellularity, normal, 
reactive, atypical, suspicious for malignancy and positive for malignancy. When only 1-2 of 
these criteria were unequivocally present, the sample was categorized as non-malignant. 
When 3-5 of these criteria were present, the sample was also examined for aneuploidy using 
UroVysion® FISH (Abbot). With 6-7 criteria present the sample was categorized as positive 
for malignancy.  
To analyze ploidy a new ThinPrep specimen was prepared. The slide was fixed for 10 
minutes according to Carnoy (3 parts methanol and 1 part acetic acid), pretreated in 2xSSC 
for 2 minutes at 73°C, and taken for pepsin digestion (pepsin 10 mg/mL in 0.01M HCl) at 
37°C for 10 minutes. Following washes in PBS the sample was refixed in 10% acid free 
formaldehyde, also containing 50mM MgCl2. After washing and dehydration through graded 
ethanols, the sample was air-dried.  The UroVysion® FISH probes (Abbot) were added, 
denaturing the sample at 73°C for 2 minutes followed by hybridization at 39°C for 20 hours 
(overnight). Stringency wash was performed using 0.4xSSC with 0.4% IgepalCA-630 at 
73°C for 2 minutes. After subsequent washings, first in 2xSSC containing 0.1% IgepalCA-
630 followed by distilled water, the sample was left to dry in the dark. Nuclei were contrast 
stained by DAPI. Slides were mounted and analyzed in the UV microscope. 
Interpretation followed the manufacturer´s recommendation, evaluating a minimum of 25 
morphologically abnormal nuclei. Samples with less than 25 cells available for evaluation 
were recorded as insufficient. Malignant criteria were met when at least four nuclei showed 
increased number of fluorescent signals (exceeding three signals for at least two of the 
studied chromosomes 3, 7 or 17); or when at least 12 nuclei lacked both fluorescent signals 
for the p16INK4A gene located at 9p21 locus. Care was taken not to over interpret double 
chromosome settings (tetraploidy) or increased number of signals due to proliferating cells. 
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Figure 7 Flowchart illustrating the diagnostic algorithm for biliary brush cytology and 
sequential use of fluorescence in-situ hybridization for detection of cholangiocarcinoma  
3.4.4 Reference standard and follow-up 
The definite diagnosis of the evaluated strictures was determined after 12 months of follow-
up. Data were collected from the electronic medical record system or, in cases were follow-
up was done by other caregivers, by retrieving information in a standardized form. CCA was 
defined by the presence of an adenocarcinoma, including carcinoma in-situ, in biopsy 
specimens, explanted livers or liver resections. Presence of low- or high-grade dysplasia in 
surgical specimens was noted. In cases were a histopathological diagnosis was missing, CCA 
was defined as a mass lesion with typical features seen on cross-sectional imaging. Patients 
were classified as benign if a sufficient follow-up after 12 months showed no signs of 
malignancy. Clinical routine for PSC patients with significant biliary strictures at our 
institution is to obtain liver function tests, and CA 19-9 at least every 6 months. Abdominal 
imaging by MR/MRCP or, if contraindicated, by ultrasound is done annually. Patients 
without complete follow-up after 12 months were excluded from analyses. 
The sensitivity, specificity, NPV and PPV was assessed using the result of the index biliary 
brushing during the study period. If simultaneous multiple brushings from different locations 
were performed the most severe result was registered for analysis of diagnostic accuracy. A 
positive index brush cytology test was defined as cytology positive for malignancy or with a 
positive FISH. A negative brush cytology index test was defined as cytology categorized as 
benign or atypical/suspicious with a negative FISH finding. All samples with inadequate 
cellularity were considered negative. Primary outcome measure was the diagnostic accuracy 
using CCA as positive endpoint. We also calculated diagnostic accuracy including HGD and 
LGD as positive endpoints. 
Biliary brushing 
Cytology criteria applied 
1-2 criteria present 6-7 criteria present 3-5 criteria present 
FISH 
Benign Malignant 
Negative Positive 
Suggestive of 
malignancy 
Atypical or 
Suspicious  
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3.4.5 Statistics 
Descriptive statistics are presented as frequencies, median values and range. Confidence 
intervals for sensitivity, specificity, PPV and NPV were obtained using the exact binomial 
interval. All analyses were carried out using STATA 13.1, StataCorp LP, College Station, 
TX, USA. 
3.5 PAPER IV 
3.5.1 Study population 
The study cohort of Paper IV consisted of patients recruited at the outpatient clinic or at the 
Endoscopy Unit at the Center for Digestive Diseases, Karolinska University Hospital. In 
addition healthy volunteers were also included. The study was approved by the regional 
ethics committee, Stockholm County (Dnr 2013/2285-31/3 and 2013/2084-31/2), and written 
informed consent was obtained from all participants. PSC patients had a confirmed diagnosis 
of PSC with cholangiographic changes demonstrated by MRCP and/or ERCP (e.g. multifocal 
intra- and/or extrahepatic strictures, beading or narrowing of bile ducts) (49). All UC patients 
had diagnosis based on clinical, endoscopic and histopathological findings consistent with 
diagnosis (212). Patients with PBC were likewise diagnosed upon typical clinical, 
biochemical and, in some cases, histopathological findings (49). Blood samples for analysis 
of peripheral blood mononuclear cells (PBMCs) were collected in healthy donors (n=12), UC 
patients (n=7), PBC patients (n=8) and PSC patients with and without IBD (n=2(). A second 
group of patients were sampled for analysis of PBMCs and biliary brush samples; PSC 
patients (n=8) and controls (n=12) (patients undergoing ERCP with biliary brush cytology for 
other indications than PSC).  
3.5.2 Study material – collection and procession of samples 
Peripheral blood mononuclear cells (PBMCs) were isolated by standard density-gradient 
separation and cryopreserved for deferred analysis. 
Biliary brush samples were collected during ERCP. All samples were directly transferred into 
complete RPMI medium (RPMI 1640 medium (Thermo Fisher Scientific) containing 10% 
FCS (Thermo Fisher Scientific) and 1 mM L-glutamin (Invitrogen)) followed by an 
enzymatic digestion using collagenase II (0.25mg/mL, Sigma-Aldrich, St. Louis, Mo) and 
DNase (0.2 mg/mL; Roche, Mannheim, Germany) in RPMI 1640 medium without FCS for 
15min at 37°C. After the digestion, complete RPMI medium was added and the cytobrushes 
were flushed with PBS. To increase cell yield, all medium/cell containing tubes were pooled, 
pelleted, and subsequently used for flow cytometry. 
3.5.3 Flow cytometry 
Cryopreserved PBMCs were thawed and stained with fluorescently labeled antibodies. 
Surface and intracellular staining was performed as previously described (213). Samples were 
acquired on a LSRFortessa flow cytometer (BD Biosciences) equipped with five lasers. Data 
  33 
were analyzed using the FlowJo software. For high dimensional analysis of flow cytometry 
data, Barnes-Hut stochastic neighbor embedding (SNE) analysis was performed using R (The 
R Foundation for Statistical Computing) with an in-house built script as previously described 
(214). 
3.5.4 In vitro MAIT cell functional assays 
Functional analysis of MAIT cells was performed as previously described (213). Briefly, 
PBMCs were stimulated for 24 h with fixed E. coli or with a combination of IL-12 (10 
ng/mL, Peprotech) and IL-18 (100 ng/mL, Medical & Biological Laboratories). To assess 
degranulation, anti-CD107a mAb was added at the beginning of the assay. In the E. coli-
mediated stimulation assays, anti-MR1 mAb (clone 26.5, Biolegend) or IgG2a isotype control 
(clone MOPC-173, Biolegend) was added at the beginning of the assay at the final 
concentration of 20 µg/mL to assess which responses were MR1-dependent. Golgi Stop 
(Monensin, BD Biosciences) and Golgi Plug (brefeldin A, BD Biosciences) were added for 
the last 6 h of the incubation. 
3.5.5 Statistical analyses 
Statistical analyses were performed using Prism software v.6 (GraphPad). The distribution of 
all datasets was assessed by D’Agostino and Person normality test. Paired two-sided t-tests 
were performed for normally distributed data sets. Two-sided Wilcoxon matched-pairs signed 
rank test was used for non-normally distributed data sets. * p < 0.05; ** p < 0.01; *** p < 
0.001. 
 
  
 34 
4 RESULTS 
4.1 PAPER I 
The final study cohort consisted of 8,932 patients, including 141 PSC patients, registered in 
GallRiks from the 1st of January 2007 until the 31st of December 2009.  
PSC patients were younger than non-PSC patients (45 years ±16 vs. 69 years ±16, P<0.001) 
and showed a male predominance (62% vs. 44%, P<0.001). More interventions were done in 
the PSC-group such as balloon dilatations (29% vs. 4%, P<0.001), brushings (51% vs. 8%, 
P<0.001) and biopsies (8% vs. 4%, P=0.05). The procedure was also longer (51 min vs. 35 
min, P<0.001) and prophylactic antibiotics given to a larger extent (49% vs. 36%, P<0.001). 
Patient- and procedure related characteristics are summarized in table 1.  
During the follow-up period of 30-days a total of 33 adverse events occurred in the PSC 
group compared with 706 in the non-PSC group. The rate of adverse events overall was 
higher in PSC patients (18.4% vs. 7.3%, P<0.001), as was the occurrence of PEP (7.8% vs. 
3.2%, P<0.002), cholangitis (7.1% vs. 2.1%, P<0.001) and extravasation of contrast (5.7% vs. 
0.7%, P<0.001). Adverse events in PSC and non-PSC patients are summarized in table 2. 
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Table 1 Comparison of procedure related characteristics in 8932 PSC and non-PSC patients 
undergoing ERCP 2007-2009 
 
Table 2 Adverse events observed during prospective follow-up in PSC and non-PSC patients 
4.1.1 Pancreatitis 
PSC was a risk factor for PEP both by univariate analysis and in the final predictive model, 
OR 2.54 (95% CI 1.36 – 4.76) and aOR 2.02 (95% CI 1.04-3.92). Other identified 
independent risk factors were cannulation of the pancreatic duct, aOR 2.60 (95% CI 2.04-
3.32) and female sex, aOR 1.32 (95% CI 1.04-1.68). A longer duration of the procedure was 
also associated with an increased risk of PEP. Factors associated with a decreased risk of PEP 
were presence of a biliary stent, aOR 0.38 (95% CI, 0.15-0.95), a significant bile duct 
stricture, aOR 0.63 (95% CI, 0.48-0.83) and high age. Table 3 and 4 shows crude ORs for all 
risk factors evaluated and aORs in the final predictive model. The prognostic model was well 
calibrated (Hosmer-Lemeshow p=0.32) and the AUROC-value was 0.70. Variables evaluated 
in the prognostic model were age, sex, procedure time, ASA classification, PSC, cannulation 
Characteristics PSC (n=141) Non-PSC (n=8791) P value 
Hospital level 
University* 
High-volume** 
 
84 (60%) 
60 (43%) 
 
2036 (23%) 
1604 (18%) 
 
<0.001 
<0.001 
Priority – elective 115 (82%) 2656 (30%) <0.001 
Duration of procedure,  
Minutes (mean, SD) 
51±34 35±22 <0.001 
Prophylactic antibiotics 69 (49%) 3153 (36%) 0.002 
Previous sphincterotomy 26 (18%) 709 (8%) <0.001 
Sphincterotomy 50 (35%) 5554 (63%) <0.001 
Precut sphincterotomy 15 (11%) 756 (9%) 0.854 
Failed cannulation of bile duct 10 (7%) 854 (10%) 0.277 
Cannulation of pancreatic duct 44 (31%) 2472 (28%) 0.419 
Significant bile duct stricture  88 (62%) 2836 (32%) <0.001 
Balloon dilation of biliary 
stricture 
41 (29%) 313 (4%) <0.001 
Pancreatic stent placement 2 (1.4%) 63 (0.6%) 0.417 
Biliary stent placement 38 (27%) 3226 (37%) 0.017 
Stent removal/replacement 9 (6%) 508 (6%) 0.760 
Biopsy 11 (8%) 382 (4%) 0.05 
Brush cytology 72 (51%) 714 (8%) <0.001 
Stone extraction 8 (6%) 2862 (33%) <0.001 
Cholangioscopy 20 (14%) 17 (0.2%) <0.001 
Adverse events PSC (n=141) Non-PSC (n=8791) P value 
Any adverse event 26 (18.4%) 640 (7.3%) <0.001 
Post ERCP pancreatitis 11 (7.8%) 283 (3.2%) 0.002 
Cholangitis 10 (7.1%) 188 (2.1%) <0.001 
Bleeding 1 (0.7%) 88 (1.0%) 0.729 
Perforation 1 (0.7%) 32 (0.4%) 0.503 
Extravasation of contrast 8 (5.7%) 60 (0.7%) <0.001 
Per-operative bleeding 2 (1.4%) 55 (0.6%) 0.241 
Total adverse events 33 (23.6%) 706 (8.0%) <0.001 
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of pancreatic duct, sphincterotomy classification, previous stent, biliary stent placement, 
pancreatic stent placement, stent extraction, cholangioscopy and significant bile duct 
stricture. 
Notably, in a subgroup analysis of the PSC patients, the PEP-rate of patients with naïve 
papillas was 11/115 (9.6%) and none of the PSC patients who had a previous sphincterotomy 
(n=26) developed PEP. This group was however to small to make any reliable statistical 
inference on risk factors.  
4.1.2 Cholangitis 
PSC was associated with an increased risk of cholangitis by univariate analysis, OR 3.81 
(95% CI 1.96 – 7.40). This association remained in the predictive model together with two 
more patient- and procedure-related variables; PSC, aOR 2.88 (95% CI, 1.47-5.65); a 
significant bile duct stricture, aOR 2.12 (95%, CI 1.55-2.89) and a longer duration of the 
procedure. Subgroup analysis did not show any association between prophylactic antibiotics 
and cholangitis in PSC patients (data not shown). Table 3 and 4 shows crude ORs for all risk 
factors evaluated and aORs in the final predictive model. The prognostic model was well 
calibrated (Hosmer-Lemeshow, p=0.74) and the AUROC-value was 0.66. Variables 
evaluated in the model were sex, procedure time, PSC, prophylactic antibiotics, 
sphincterotomy classification, dilation of biliary stricture, biliary stone extraction, previous 
stent, biliary stent placement, pancreatic stent placement, number of stents, stent extraction, 
biliary brush cytology, cholangioscopy and significant bile duct stricture.  
4.1.3 Extravasation of contrast 
The risk of extravasation of contrast was associated with variables signaling procedural 
technical problems. In the predictive model, increased risk was found for; PSC, aOR 5.84 
(95% CI, 2.24-15.23), when the cannulation of the bile duct failed, aOR 6.34 (95% CI, 3.74-
10.71) and if cannulation of the pancreatic duct was done, aOR 2.59 (95% CI, 1.56-4.29). 
Longer duration of the procedure and cholangioscopy, aOR 5.25 (95% CI, 1.31-20.92) were 
other variables associated with increased risk (table 3 and 4). The prognostic model was well 
calibrated (Hosmer-Lemeshow p=0.60) and the AUROC-value was 0.84. Variables included 
in the predictive model were procedure time, PSC, cannulation of biliary duct, cannulation of 
pancreatic duct, sphincterotomy classification, dilation of biliary stenosis, number of stents, 
biliary stone extraction, previous stent and biliary brush cytology.  
4.1.4 Adverse events overall 
The unadjusted risk for an adverse event was increased in PSC patients, OR 2.88 (95% CI 
1.87 – 4.44). Four different variables were associated with increased risk for adverse events 
overall in the predictive model; PSC, aOR 2.11 (95% CI, 1.32-3.37), cannulation of the 
pancreatic duct, aOR 1.74 (95% CI, 1.46-2.05) and for dilation of a biliary stenosis, aOR 1.55 
(95% CI, 1.07-2.23). The risk also increased with the time of the procedure. Factors 
associated with decreased risk were; biliary stone extraction aOR 0.81 (95% CI, 0.66-0.99), 
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the presence of a significant bile duct stricture, aOR 0.73 (95% CI, 0.61-0.91) and higher age 
(table 3 and 4). The prognostic model was well calibrated (Hosmer-Lemeshow p=0.57) and 
the AUROC-value was 0.65. Variables evaluated in the prognostic model were age, sex, 
procedure time, ASA classification, prophylactic antibiotics, PSC, cannulation of pancreatic 
duct, cannulation of bile duct, sphincterotomy classification, dilation of biliary stenosis, 
biliary stone extraction, previous stent, biliary stent placement, pancreatic stent placement, 
stent extraction, biliary brush cytology, cholangioscopy, number of stents and significant bile 
duct stricture. 
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Table 3 Unadjusted risk estimates for patient- and procedure related risk factors for adverse 
events overall, pancreatitis, cholangitis and extravasation of contrast. Values are odds ratios 
(ORs). 
 
 Adverse events overall Pancreatitis Cholangitis Extravasation of contrast 
Variable n Univariate n Univariate n Univariate n Univariate 
Age 
>80 years 
71-80 years 
61-70 years 
18-60 years 
 
147 
179 
135 
205 
 
0.63 (0.50-0.78)* 
0.85 (0.69-1.05) 
0.76 (0.61-0.95)* 
Reference group 
 
49 
79 
61 
105 
 
0.41 (0.29-0.58)* 
0.73 (0.55-0.99)* 
0.67 (0.49-0.93)* 
Reference group 
 
46 
48 
35 
43 
 
1.05 (0.68-1.60) 
1.15 (0.75-1.74) 
0.98 (0.62-1.53) 
Reference group 
 
15 
13 
18 
22 
 
0.61 (0.31-1.19) 
0.58 (0.29-1.16) 
0.96 (0.51-1.80) 
Reference group 
Sex 
Women 
Man 
 
377 
289 
 
1.06 (0.90-1.24) 
Reference group 
 
180 
114 
 
1.29 (1.02-1.64)* 
Reference group 
 
97 
81 
 
0.88 (0.65-1.19) 
Reference group 
 
40 
28 
 
1.16 (0.71-1.88) 
Reference group 
ASA score 
3-5 
1-2 
 
322 
344 
 
0.91 (0.78-1.07) 
Reference group 
 
124 
170 
 
0.71 (0.56-0.90)* 
Reference group 
 
95 
77 
 
1.23 (0.91-1.67) 
Reference group 
 
35 
33 
 
1.04 (0.64-1.67) 
Reference group 
Priority 
Urgent 
Elective 
 
444 
222 
 
0.89 (0.75-1.05) 
Reference group 
 
179 
115 
 
0.69 (0.54-0.88)* 
Reference group 
 
120 
52 
 
1.22 (0.88-1.69) 
Reference group 
 
45 
23 
 
0.87 (0.52-1.44) 
Reference group 
PSC 26 2.88 (1.87-4.44)* 11 2.54 (1.36-4.76)* 10 3.81 (1.96-7.40)* 8 8.65 (4.05-18.44)* 
Profylactic antibiotics 252 1.08 (0.91-1.28) 111 1.04 (0.81-1.33) 73 1.05 (0.78-1.43) 32 1.64 (0.99-2.73) 
Procedure time 
>45 min 
31-45 min 
21-30 min 
≤20 min 
 
235 
170 
148 
113 
 
2.86 (2.27-3.61)* 
2.04 (1.60-2.61)* 
1.58 (1.23-2.03)* 
Reference group 
 
97 
70 
74 
53 
 
2.40 (1.71-3.37)* 
1.74 (1.21-2.50)* 
1.66 (1.16-2.38)* 
Reference group 
 
53 
50 
41 
28 
 
2.56 (1.61-4.06)* 
2.41 (1.51-3.84)* 
1.77 (1.09-2.87)* 
Reference group 
 
35 
20 
8 
5 
 
8.83 (3.45-22.58)* 
5.12 (1.92-13.67)* 
1.85 (0.60-5.66) 
Reference group 
Significant bile duct 
stricture 
220 1.01 (0.86-1.20) 77 0.72 (0.55-0.94)* 95 2.70 (1.82-4.01)* 26 1.24 (0.76-2.03) 
Sphincterotomy 
Sphincterotomy and/or 
precut 
Previous Sphincterotomy 
No 
 
 
515 
31 
120 
 
 
1.06 (0.87-1.31) 
0.55 (0.37-0.83)* 
Reference group 
 
 
219 
7 
68 
 
 
0.79 (0.60-1.04) 
0.22 (0.10-0.48)* 
Reference group 
 
 
128 
19 
25 
 
 
1.33 (0.85-2.01) 
1.72  (0.94-3.15) 
Reference group 
 
 
52 
2 
14 
 
 
0.84 (0.46-1.52) 
0.30 (0.07-1.33) 
Reference group 
Cannulation of bile duct 
Failed cannulation 
Superficial cannulation 
Not attempted  
Deep cannulation 
 
 
98 
14 
8 
546 
 
 
1.69 (1.34-2.12)* 
1.42 (0.81-2.48) 
0.64 (0.31-1.32 
Reference group 
 
 
35 
2 
6 
251 
 
 
0.79 (0.55-1.14) 
2.38 (0.59-9.64) 
0.92 (0.40-2.10) 
Reference group 
 
 
11 
6 
1 
154 
 
 
0.64 (0.34-1.18) 
2.17 (0.94-5.01) 
0.29 (0.04-2.05) 
Reference group 
 
 
29 
4 
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7.66 (4.66-12.59)* 
6.30 (2.21-17.97)* 
NA 
Reference group 
Cannulation of 
pancreatic duct 
292 2.12 (1.80-2.49)* 158 3.09 (2.44-3.91)* 61 1.41 (1.02-1.93)* 41 3.91 (2.40-6.38)* 
Previous stent 31 0.62 (0.43-0.89)* 5 0.22 (0.09-0.53)* 17 1.49 (0.90-2.48) 1 0.19 (0.03-1.37) 
Stent extraction 27 0.67 (0.45-0.99)* 5 0.27 (0.11-0.67)* 16 1.67 (0.99-2.82)* 0  
Biliary stone extraction 186 0.81 (0.67-0.96) 82 0.81 (0.63-1.05) 35 2.23 (1.64-3.02)* 6 0.20 (0.09-0.46)* 
Dilation of biliary 
stenosis 
45 1.87 (1.35-2.58)* 14 1.22 (0.71-2.11) 20 3.34 (2.07-5.40)* 7 2.76 (1.25-6.08)* 
Biliary stent placement 239 0.97 (0.82-1.14) 96 0.84 (0.65-1.07) 96 2.23 (1.64-3.02)* 20 0.70 (0.21-1.18) 
Pancreatic stent 
placement 
11 2.55 (0.86-1.19) 8 4.21 (1.99-8.91)* 0  1 2.87 (0.39-21.11) 
Number of stents 
≥2 
1 
0 
 
17 
233 
416 
 
0.84 (0.51-1.39) 
1.03 (0.87-1.21) 
Reference group 
 
6 
98 
190 
 
0.65 (0.29-1.48) 
0.94 (0.74-1.21) 
Reference group 
 
7 
89 
76 
 
2.02 (0.92-4.43) 
2.16 (1.59-2.95)* 
Reference group 
 
1 
20 
47 
 
0.43 (0.06-3.17) 
0.76 (0.45-1.29) 
Reference group 
Brush cytology 70 1.24 (0.96-1.60) 30 1.18 (0.81-1.74) 25 1.66 (1.08-2.56)* 10 1.77 (0.90-3.48) 
Biospy 29 0.98 (0.67-1.45) 15 1.17 (0.69-2.00) 6 0.73 (0.32-1.66) 3 1.01 (0.32-3.24) 
Cholangioscopy 10 4.65 (2.24-9.65) 4 3.60 (1.27-10.22) 2 2.64 (0.63-11.06) 4 16.92 (5.81-49.22)* 
* p <0.05 
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Table 4 Adjusted risk estimates for patient- and procedure related risk factors from predictive 
models for adverse events overall, pancreatitis, cholangitis and extravasation of contrast. 
Values are adjusted odds ratios (aORs). 
 
 Adverse events overall Pancreatitis Cholangitis Extravasation of contrast 
Variable n Multivariate n Multivariate n Multivariate n Multivariate 
Age 
>80 years 
71-80 years 
61-70 years 
18-60 years 
 
147 
179 
135 
205 
 
0.65 (0.52-0.82)* 
0.86 (0.69-1.07) 
0.76 (0.60-0.96)* 
Reference group 
 
49 
79 
61 
105 
 
0.42 (0.30-0.60)* 
0.75 (0.55-1.03) 
0.70 (0.50-0.97)* 
Reference group 
 
46 
48 
35 
43 
  
15 
13 
18 
22 
 
Sex 
Women 
Man 
 
377 
289 
  
180 
114 
 
1.32 (1.04-1.68)* 
Reference group 
 
97 
81 
  
40 
28 
 
PSC 26 2.11 (1.32-3.37)* 11 2.02 (1.04-3.92)* 10 2.88 (1.47-5.65)* 8 5.84 (2.24-15.23)* 
Procedure time 
>45 min 
31-45 min 
21-30 min 
≤20 min 
 
235 
170 
148 
113 
 
2.43 (1.90-3.01)* 
1.86 (1.45-2.39)* 
1.54 (1.20-1.99)* 
Reference group 
 
97 
70 
74 
53 
 
2.02 (1.41-2.88)* 
1.55 (1.07-2.25)* 
1.63 (1.13-2.34)* 
Reference group 
 
53 
50 
41 
28 
 
2.09 (1.31-3.34)* 
2.06 (1.29-3.31)* 
1.60 (0.98-2.61) 
Reference group 
 
35 
20 
8 
5 
 
3.95 (1.49-10.45)* 
2.99 (1.10-8.11)* 
1.49 (0.48-4.59) 
Reference group 
Significant bile duct 
stricture 
220 0.73 (0.61-0.91)* 77 0.63 (0.48-0.83)* 95 2.12 (1.55-2.89)* 26  
Sphincterotomy 
Sphincterotomy and/or 
precut 
Previous Sphincterotomy 
No 
 
 
515 
31 
120 
 
 
1.10 (0.88-1.37) 
0.63 (0.42-0.96)* 
Reference group 
 
 
219 
7 
68 
 
 
0.70 (0.53-0.93)* 
0.32 (0.14-0.73)* 
Reference group 
 
 
128 
19 
25 
  
 
52 
2 
14 
 
 
 
 
 
Cannulation of bile duct 
Failed cannulation 
Superficial cannulation 
Not attempted  
Deep cannulation 
 
 
98 
14 
8 
546 
  
 
35 
2 
6 
251 
  
 
11 
6 
1 
154 
  
 
29 
4 
 
35 
 
 
6.34 (3.74-10.71)* 
4.61 (1.59-13.41)* 
NA 
Reference group 
Cannulation of 
pancreatic duct 
292 1.74 (1.46-2.05)* 158 2.60 (2.04-3.32)* 61  41 2.59 (1.56-4.29)* 
Previous stent 31  5 0.38 (0.15-0.95)* 17  1  
Biliary stone extraction 186 0.81 (0.66-0.99)* 82  35  6  
Dilation of biliary 
stenosis 
45 1.55 (1.07-2.23)* 14  20  7  
Cholangioscopy 10  4  2  4 5.25 (1.31-20.92)* 
NA –not applicable, * p< 0.05 
4.2 PAPER II 
The final study cohort consisted of 47 PSC patients with a median age of 40 (range 22-70), 
and male predominance (70%). The indications for ERCP were: jaundice in 28% (13/47); a 
suspected malignant stricture on MRCP in 62% (29/47); and need of stent exchange in 9% 
(5/47). Table 5 shows the clinical characteristics of patients included. 
4.2.1 Technical evaluation – feasibility  
The SOC procedure was considered technically successful in 96% (45/47) of cases. In the 
two unsuccessful investigations one failed due to technical issues with the SOC-probe and 
one due to difficulties to pass the scope into the biliary duct. Table 6 summarizes clinical 
information and technical aspects of the ERCP and SOC procedure in the 45 patients with a 
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technical success. In total, 64 strictures were evaluated with SOC: 23% (15/64) were present 
in the common bile duct, 20% (13/64) in the common hepatic duct, 11% (7/64) were hilar 
strictures, 34% (22/64) were strictures of the left or right hepatic duct and 11% (7/64) were 
segmental duct strictures. Table 7 summarizes the location, appearance and sampling of the 
64 strictures evaluated. Strictures were inspected and passed in 50 cases and only inspected 
but not passed in 14. The locations of the investigated biliary strictures are shown in Figure 8.  
Table 5 Clinical characteristics and indications for ERCP with SOC in 45 PSC patients 
Age, median (range), years 40 (22-70) 
Duration of PSC at time of SOC investigation,  
median (range), years 
6,4 (0-35.9) 
Male sex, n (%) 33 (70%) 
Follow-up time, median (range), months 27 (2-64) 
IBD 
Ulcerative colitis, n (%) 
Crohn’s Disease, n (%) 
No IBD, n (%) 
 
30 (64%) 
6 (13%) 
11 (23%) 
Indication for ERCP/SOC  
Jaundice, n (%) 
Stricture with suspicion of malignancy, n (%) 
Change or extraction of stent, n (%) 
 
13 (28 %) 
29 (62%) 
5 (9%) 
 
Table 6 Summary of clinical information and technical aspects of ERCP procedures with 
SOC in 45 patients with PSC 
 n (%) 
Endoscopic sphincterotomy (ES)  
No ES 
ES performed 
ES previously performed 
 
5 (11%) 
13 (29%) 
27 (60%)  
Presence of bile duct stones 
Successful removal of the stones  
12 (27%) 
11 (92%)  
Majoie Score  
 
Intrahepatic 
Type 0 
Type I 
Type II 
Type III 
 
 
 
0 
8 (18%) 
34 (76%) 
3 (7%) 
Extrahepatic 
Type 0 
Type I 
Type II 
Type III 
Type IV 
 
2 (4%) 
10 (22%) 
25 (56%) 
8 (18%) 
0 
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Table 7 Information on location, sampling and macroscopic appearance of 64 strictures in 45 
PSC patients evaluated with SOC 
 n (%) 
Location of investigated strictures 
Common bile duct 
Common hepatic duct 
Hilar 
Left or right hepatic duct 
Segmental ducts 
 
15 (23%) 
13 (20%) 
7 (11%) 
22 (34%) 
7 (11%) 
Biliary brush samples 63 (98%) 
Biopsy by mini-forceps 22 (34%) 
Passed strictures 50 (78%) 
Strictures inspected 
Before dilatation 
After dilatation 
After stone extraction 
 
50 (78%) 
13 (20%) 
1 (2%) 
Macroscopic appearance of strictures 
Malignant 
Suspicious 
Normal 
 
1 (2%) 
3 (5%) 
60 (93%) 
 
4.2.2 Adverse events 
Adverse events occurred in a total of 15% percent (7/47) of patients. Mild PEP was 
diagnosed in 4 patients. Cholangitis was seen in 2 patients. One patient had mild cholangitis 
treated with per oral antibiotics. One patient had severe bacterial cholangitis and cholecystitis. 
A majority of all adverse events (71%, 5/7) occurred in the first 15 patients. 
4.2.3 Sampling, end-points and diagnostic accuracy 
Sampling results of biliary brush cytology and ductal biopsies are presented in table 8. 
Cellularity was sufficient in 95% (21/22) of the mini-forceps biopsies and in 98% (62/63) of 
the biliary brushings. The median follow-up time was twenty-eight months (range 2 – 64 
months) during which three patients were diagnosed with CCA. One patient presented with a 
macroscopic appearance categorized as malignant on cholangioscopy and findings positive 
for malignancy on both cytology and biopsy. The second patient had an intrahepatic CCA 
diagnosed 17 months after inclusion. The third patient was diagnosed with a perihilar CCA at 
the time of LTx after 35 months of follow-up. Of the remaining 42 PSC patients, 19 
underwent LTx with no signs of CCA in the explanted liver although HGD was detected in 4. 
Two patients with strong suspicion of cancer underwent hepatic resection. The resected 
specimens were negative for cancer in both cases. Median follow-up time in the 21 patients 
with final status determined by clinical course was 47 months (range 17-64). 
The sensitivity of detection of CCA with cholangioscopy-guided sampling was 33% (95% CI 
1-91%), the specificity 100% (95% CI 92-100%), PPV 100% (95% CI 3-100%), NPV 95% 
(95% CI 85-99%) and diagnostic accuracy 96% (95% CI 85-100%). 
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Figure 8 Location of 64 strictures in 45 patients with PSC, and whether the cholangioscope 
could pass the stricture. CBD, common bile duct; CHD, common hepatic duct; CD, cystic 
duct; LHD, left hepatic duct; RHD, right hepatic duct. Numbers indicate segmental bile ducts  
4.2.4 Additional technical value 
The criteria for the outcome technical advantage was met in four patients (9%) were the 
target lesion could not have been reached without the options offered by the cholangioscopic 
visualization. Notably, bile duct stones were found in 12 cases (27%); these could be 
evacuated and the strictures dilated. In 20% (13/64) of cases the stricture required dilatation 
before inspection. 
4.2.5 Endoscopic appearance of bile ducts in PSC 
A thin fibrotic circular narrowing of the bile duct, which was easily dilated, was a common 
finding. These lesions were observed either proximal or distal to a stricture, or sometimes 
both. In three patients strictures with an appearance that raised suspicion of malignancy were 
found. None of them had sampling results categorized as dysplastic (data not shown). 
Furthermore, all four patients with HGD detected in explanted livers were considered to have 
benign conditions at endoscopy. 
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Table 8 Sampling results of biliary brush cytology and ductal biopsies of evaluated strictures 
in 45 PSC patients 
 Result 
 Inadequate Normal Reactive Atypical Suspicious Malignancy 
Brush cytology 
(n=63) 
1 (2%) 45 (71%) 2 (3%) 7 (11%) 6 (10%) 2 (3%) 
 Inadequate Normal Reactive LGD HGD Malignancy 
Biopsy (n=22) 1 (5%) 13 (59%) 3 (14%) 0 (0%) 4 (18%) 1 (5%) 
 
4.3 PAPER III 
During the study period, 2009-2015, a total of 214 PSC patients underwent ERCP with 
biliary brush cytology. Incomplete follow-up, other or unidentified malignancy in 6 patients 
left 208 individuals eligible for analysis. The study design, brush cytology results and 
endpoints are summarized in Figure 9. The median age of the patients was 40.8 years and 
68% were men. The most common indication for ERCP with brushings was stricture(s) with 
suspicion of malignancy (77%), followed by cholestatic symptoms (22%). In two patients 
(1%) cross-sectional imaging showed definite signs of a biliary malignancy prior to the 
ERCP. Clinical characteristics and indications for ERCP are presented in Table 9. 
4.3.1 Cytology results and endpoints 
Most patients (68%) had benign cytological findings and one sample (0.5%) was reported 
malignant based on cytomorphology from the index brushing. In the remaining 62 patients 
with equivocal cytology, a positive FISH result was detected in 31%. Results of the index 
biliary brush cytologies are presented in Table 10. Insufficient material for conventional 
cytology was low (1%), although higher for FISH analysis, 15-17% was found to be 
insufficient when the definition of more than 25 morphologically abnormal nuclei available 
for FISH evaluation was applied. 
CCA was confirmed in 15 patients (7%) based on histology and/or imaging during follow-up. 
A histopathological diagnosis was made from the following specimens: Biopsy from primary 
tumor or metastasis (n=3); surgical resection (n=5) and; explanted liver (n=6). Radiographic 
findings alone confirmed the cancer diagnosis in one patient. In total, 45 patients underwent 
LTx, liver resection or had a biopsy from suspected lesions during the 12 months’ follow-up. 
Among the 34 transplanted patients, 3 (10%) were shown to have HGD, and 5 (17%) to have 
LGD in the explanted liver. Diagnostic endpoints after 12 months of follow-up are 
summarized in Table 11 and Figure 9.  
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Figure 9 Summary of inclusion process, results from biliary brush cytology and FISH, and 
end-points after 12 months of follow-up 
4.3.2 Diagnostic performance 
The diagnostic performance for detection of CCA in all 208 cases by brush cytology, 
including FISH in equivocal cases, had a sensitivity, specificity, PPV, NPV and accuracy of 
80% (95%CI 52-96%), 96% (95%CI 92-98%), 60% (95%CI 36-81%), 98% (95%CI 95-
100%) and 95% (95% CI 91-97%), respectively. 
To rule out biliary dysplasia and CCA in patients with PSC is well known to be 
inconceivable. Therefore, we tested the diagnostic performance in the subgroup of patients in 
whom a confirmed follow-up diagnosis were obtained by either LTx, liver resection, biopsy 
or cancer related death (n=46). For CCA and HGD the sensitivity, specificity, NPV decreased 
to 83% (95% CI 59-96%), 82% (95% CI 63-94%), and 89% (95% CI 70-98%) and the PPV 
increased to 75% (95% CI 51-91%). The diagnostic performance for detection of CCA, HGD 
and LGD by routine cytology and FISH is summarized in Table 12. 
4.3.3 Diagnostic performance in patients with equivocal cytology 
In clinical practice, a major problem is the interpretation of equivocal cytology in patients 
without conclusive imaging results. Current guidelines recommend FISH in equivocal cases 
(47). Therefore, we investigated the diagnostic accuracy in this subgroup of patients. 
Sensitivity, specificity, NPV, PPV and accuracy were calculated in patients with equivocal 
brush cytology results and no evident malignancy on imaging prior to sampling (n=61). A 
positive FISH result was detected in 19 (31%) of these patients and 11 (18%) were diagnosed 
208 
PSC patients 
62 
Equivocal FISH 
43 Negative 
19 Positive 
214  
PSC patients 
6 patients excluded 
1 Colorectal cancer 
1 Unknown malignancy 
4 Incomplete follow-up 1 Malignant 
145 
Benign 
1 CCA 
41 Benign 
11 CCA 
2 Benign 
1 CCA 
142 Benign 
2 CCA 
Endpoint Brush cytology and FISH Selection of Patients 
3 LGD 
1 LGD 
1 LGD 
3 HGD 
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with CCA during follow-up. Sensitivity, specificity, PPV and NPV for CCA alone in this 
group was 100% (95%CI 72-100%), 84% (95%CI 71-93%), 58% (95%CI 34-80%) and 
100% (95%CI 92-100%). Results for detecting CCA, HGD and LGD are presented in Table 
12.  
Table 9 Clinical characteristics and results of serum CA 19-9 and imaging in 208 PSC 
patients at inclusion 
 
Age, years (median, range) 40.8 years (18.4-77.5) 
Sex, n (%) 
Female 
Male 
 
66 (32%) 
142 (68%) 
IBD, n (%) 
No IBD 
UC 
Mb Crohn 
Indeterminate colitis 
Unknown 
 
33 (16%) 
135 (65%) 
33 (16%) 
5 (2%) 
2 (1%) 
Duration of PSC, years (median, range) 5.6  (0-41) 
Bilirubin (median, range) (n=197) 
(Normal range <26µmol/L ) 14 mmol/L (3-410) 
ALP (median, range) (n=183) 
(Normal range <1,9 µkat/L) 3.7 µkat/L (0.7-30.3) 
CA 19-9 (median, range) (n=117) 
<20 kU/L n,(%) 
<120 kU/L n (%) 
15 kU/L (0.3-18220) 
50 (43%) 
16 (14%) 
Results of MRI/MRCP (n=121) 
Definite biliary malignancy, n (%) 
Suspicion of malignancy, n (%) 
No suspicion of malignancy, n (%) 
 
1 (1%) 
71 (59%) 
49 (40%) 
Indications for ERCP 
Malignancy, n (%) 
Cholestatic symptoms, n (%) 
Stricture with suspicion of malignancy, n (%) 
 
2 (1%) 
45 (22%) 
161 (77%) 
 
Table 10 Results of biliary brush cytology and FISH analysis in 208 PSC patients at the 
index ERCP 
 
Conventional cytology  n (%) FISH n (%) 
Inadequate cellularity 3 (1%)  - 
Benign 142 (68%)  - 
Atypical 33 (16%) Insufficient material 
Negative 
Positive 
5 (15%) 
27 (82%) 
1 (3%) 
Suspicious for 
malignancy 
29 (14%) Insufficient material 
Negative 
Positive 
5 (17%) 
6 (21%) 
18 (62%) 
Malignancy 1 (0.5%)  - 
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Table 11 Endpoints and method of ascertainment after 12 months of follow up in 208 PSC 
patients undergoing biliary brush cytology 
Final diagnosis 
Method for diagnosis 
Benign CCA  HGD LGD Total 
Clinical follow up with no signs 
of malignancy 
162 - - - 162 
LTx 20 6 3 5 34 
Surgical resection 
 Liver resection 
 Whipple 
 
3 
- 
 
3 
2 
 
- 
- 
 
- 
- 
 
6 
2 
Biopsy - 3 - - 3 
Cross-sectional imaging only - 1 - - 1 
Total 185 15 3 5 208 
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Table 12 Diagnostic performance of biliary brush cytology with sequential FISH for 
detecting CCA and dysplasia in index brushing of 208 PSC patients and in 61 PSC patients 
with equivocal cytology and no definitive evidence for CCA on imaging. 
Diagnostic performance in all patients (n=208) 
 
Sensitivity % 
(95%CI) 
Specificity % 
(95%CI) 
PPV % 
(95%CI) 
NPV %   
(95%CI) 
Accuracy  
(95% CI) 
CCA 80% (52-96%) 96% (92-98%) 60% (36-81%) 98% (95-100%) 95% (91-97%) 
Analysis restricted to patients with confirmed diagnosis by LTx, surgical resection, biopsy or cancer related death 
(n=46) 
CCA 80% (52-96%) 74% (55-88%) 60% (36-81%) 89% (70-98%) 76% (61-87%) 
CCA+HGD 83% (59-96%) 82% (63-94%) 75% (51-91%) 89% (70-98%) 82% (69-92%) 
CCA+HGD+LGD 78% (56-93%) 91% (72-99%) 90% (68-99%) 81% (61-93%) 85% (71-94%) 
Diagnostic performance of FISH in patients with equivocal cytology without definitive evidence of CCA on imaging 
(n=61) 
CCA 100% (72-100%) 84% (71-93%) 58% (34-78%) 100% (92-100%) 87% (76-94%) 
CCA+HGD 100% (77-100%) 55% (23-83%) 74% (49-91%) 100% (54-100%) 80% (59-93%) 
CCA+HGD+LGD 94% (73-100%) 71% (29-96%) 90% (67-99%) 83% (36-100%) 88% (69-97%) 
 
4.4 PAPER IV 
4.4.1 MAIT cells in peripheral blood of PSC patients 
MAIT cells can be defined in humans as T cells expressing the TCR Vα7.2 segment in 
combination with expressing high levels of CD161 (Figure 10, and 11A) (215). We first 
analyzed the frequency of MAIT cells in patients with PSC compared to IBD and PBC as 
well as to healthy controls (see Table 13 for patient characteristics). The frequency of MAIT 
cells was reduced in the PSC patients (median: 0.75%, range: 0.13-5.2%) as compared to 
healthy controls (median: 2.23%, range: 0.57-4.40%) (Figure 11B). A similar reduction in 
MAIT cells was also noted for IBD and PBC patients (Figure 11B). The Vα7.2+CD161- T 
cell population was used as a reference population. When analyzing the levels of these cells, 
no difference was noted in the patient cohorts as compared to healthy controls (Figure 11B). 
The MAIT cell loss affected both the CD8+ and the CD8- MAIT cell subsets (Figure 11C). 
Taken together, these data indicate that the peripheral blood MAIT cell population was 
substantially reduced in PSC. However, since similar reductions were noted within disease 
control cohorts (IBD, intestinal inflammation; PBC, autoimmune liver inflammation), this 
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loss did not appear to be specific for PSC but rather a common feature of chronic 
inflammatory disorders affecting these organs. 
Figure 10 Gating scheme to identify MAIT cells. To identify MAIT cells, first doublet 
events were excluded followed by identification of lymphocytes, removal of CD14+CD19+ 
and dead cells, gating for CD3+ cells, subsequent gating for CD161+Vα7.2+ cells, and finally 
removal of CD4+ cells 
 
Table 13 Clinical characteristics of study subjects from which MAIT cells in peripheral 
blood were analyzed (PBMC-cohort) 
 Healthy 
donors 
(n=12) 
PSC (n=28) IBD (n=7) PBC (n=8) 
Male sex, % 50% (6/12) 71% (20/28) 57% (4/7) 38% (3/8) 
Age, years (median, range) 33 (27-41) 41 (26-73) 48 (28-72) 70 (51-79) 
PSC duration, years 
(median, range) 
NA 10 (2-28) NA NA 
IBD, % 
Ulcerative colitis 
Mb Crohn 
Indeterminate colitis 
NA 82% (23/28) 
78% (18/23) 
22% (5/23) 
0% (0/23) 
100% 
(7/7) 
NA 
Bilirubin, µmol/L 
(median, range) 
NA 10.0 (5-31) NA 7 (5-82) 
ALP, µkat/L (median, range) 
 
Proportion >ULN (%) 
NA 1.9 (0.6-10.0) 
 
50% (14/28) 
NA 1.9 (1.0-3.9) 
 
38% (3/8) 
ULN –upper limit of normal range 
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Figure 11. (A) Representative flow cytometry plots for identification of Vα7.2+CD161+ 
MAIT cells in patients and controls. (B) Percentage of MAIT cells, and Vα7.2+CD161- T 
cells, out of total T cells in peripheral blood of healthy controls (n=12), patients with PSC 
(n=28), IBD (n=7), and PBC (n=8). (C) Frequency of CD8+ or double-negative MAIT cells 
out of total MAIT cells or total T cells in healthy controls and PSC patients. 
 
4.4.2 High-dimensional SNE analysis of peripheral blood MAIT cells in PSC 
Next, we performed a detailed phenotypic characterization of the residual peripheral blood 
MAIT cells in PSC patients. To this end, we simultaneously analyzed the expression of 13 
surface receptors on MAIT cells (Figure 12A). Stochastic Neighbour Embedding (SNE) was 
used for the downstream analysis. SNE is a dimensionality reduction method that generates 
two-dimensional representations of multi-dimensional data while preserving single-cell 
resolution. This method has proven well suited for analysis of complex flow cytometry data 
(214, 216). In brief, each sample was assigned an electronic barcode. Next, all samples were 
merged and analysed using Barnes-Hut SNE followed by generation of SNE maps for PSC 
patients and healthy controls (Figure 12B). Next, a residual plot was generated displaying the 
clusters of cells that varied in abundance between the two cohorts (Figure 12B). This analysis 
revealed substantial differences in the phenotype between MAIT cells from PSC patients as 
compared to healthy controls. 
As a next step, to assess which phenotypic markers were contributing to the difference in 
phenotype, the residual plot was overlaid onto individual SNE maps showing the relative 
expression of each of the 13 parameters included in the analysis (Figure 12C). This revealed 
that cells with higher CD69, CD56, and NKG2D expression as well as lower CD28, CD127, 
and CXCR6 expression was present within the PSC patient clusters as compared to in cell 
clusters from healthy controls (Figure 12C). In a separate single-parameter conventional flow 
cytometry data analysis, MAIT cells from PSC-patients also presented with higher levels of 
 50 
PD-1 and CD39 as compared to healthy controls (Figure 12D and Figure 12E). However, 
these changes were not unique to PSC but were also seen in IBD and PBC patients (Figure 
9D). Interestingly, within the Vα7.2+CD161- non-MAIT cell reference population, no 
significant differences in phenotype were observed when comparing patients with controls 
suggesting the altered phenotype to be specific to MAIT cells (Figure 12E ). 
In summary, high-dimensional SNE analysis revealed MAIT cells to present with an 
activated phenotype in PSC. 
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Figure 12 (A) Representative histograms showing expression of the indicated markers on 
total T cells and MAIT cells compared to fluorescence minus one (FMO) controls. (B) SNE 
density plot of total cells subsequently subdivided into healthy controls and PSC-patients, and 
residual plot showing the difference between the two groups. (C) SNE plots showing 
expression of the indicated markers where cells within blue circles are more abundant in 
healthy controls whereas cells within the red circles are more abundant in PSC patients. (D) 
Frequency of expression for the indicated markers on MAIT cells in healthy controls and 
patients. (E) Frequency of expression for the indicated markers on Vα7.2+CD161- T cells in 
healthy controls and patients. 
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4.4.3 MAIT cell function in response to E. coli in PSC 
Following a detailed phenotypic characterization of MAIT cells, we set out to explore their 
functional capacity upon stimulation with bacteria and cytokines. MAIT cells were assessed 
for degranulation capacity (CD107a and upregulation of granzyme B), cytokine production 
(TNF, IFNγ, and IL-17), as well as upregulation of activation markers (CD69 and CD25) in 
response to fixed E. coli or stimulation with IL-12 and IL-18 (Figure 13A). The measured 
responses to E. coli stimulation were mainly MR1-dependent (data not shown). An impaired 
MAIT cell response to E. coli stimulation was observed in the PSC-patients with reduced 
levels of CD107a, TNF, IFNγ, and CD69 (Figure 13B). This was also the case for the 
investigated disease control cohorts (Figure 13B). Compared to E. coli stimulation, only a 
minor impairment in MAIT cell function was noted after IL-12 and IL-18 stimulation with 
significantly lower levels of TNF (Figure 13C). Only very low albeit consistently detectable 
levels of IL-17 were observed upon the two stimulations but with no apparent changes in 
patients compared to controls (data not shown). 
Taken together, our results indicate that MAIT cells in PSC patients have impaired MR1-
dependent functional responses. In line with the profound depletion of MAIT cells and the 
abnormal phenotype, this is however not specific to PSC but also seen for other inflammatory 
conditions such as IBD and PBC. 
4.4.4 Characterization of MAIT cells in human bile duct 
MAIT cells are enriched in the human liver (217) and have been shown to localize in portal 
tracts and around bile ducts (92). Furthermore, cholangiocytes can present antigens and 
activate MAIT cells via MR1 (92). To assess MAIT cells present in the biliary epithelium we 
established a novel method of acquiring cells from biliary brush samples. Samples were 
obtained from PSC patients and control patients referred to endoscopic retrograde 
cholangiopancreatography (ERCP), the clinical procedure used to access the bile duct via the 
duodenum. Clinical characteristics of the investigated subjects are presented in Table 14. 
MAIT cells could readily be identified when such samples were analyzed (Figure 14A). The 
proportion of MAIT cells in biliary brush samples was elevated four-fold as compared to 
matched peripheral blood (Figure 14B). In contrast to the loss of MAIT cells observed in 
peripheral blood of PSC patients (Figure 11B), no changes in MAIT cell frequencies nor in 
absolute numbers were noted in biliary brush samples from PSC patients compared to non-
PSC patient controls (Fig 14C and D). In summary, these data show that MAIT cells were 
highly enriched in bile duct tissue compared to peripheral blood, indicating that MAIT cells 
are retained at the site of inflammation in PSC. 
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Figure 13 (A) Representative concatenated FACS plots showing CD107a, granzyme B 
(GzmB), TNF, IFNγ, CD69, and CD25 expression following co-culture with E. coli or after 
IL-12+IL-18 stimulation. (B) Summary of functional data following E. Coli stimulation 
showing expression frequencies or mean fluorescence intensity (MFI) for indicated markers 
and sample cohorts. (C) Summary of functional data following IL-12+IL-18 stimulation 
showing expression frequencies or MFI for indicated markers and sample cohorts. 
 
Figure 14 (A) Representative FACS plots of MAIT cells in matched PBMC and biliary brush 
samples. (B) Frequency of MAIT cells of total T cells in matched PBMC and biliary brush 
samples. (C) Frequency of bile duct MAIT cells out of total T cells comparing non-PSC 
controls and PSC patients. (D) Absolute number of MAIT cells obtained per biliary brush 
sample comparing non-PSC controls and PSC patients. 
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Table 14 Clinical characteristics of PSC patients and controls from which MAIT cells in bile 
duct were analyzed (biliary brush cohort). 
 PSC (n=8) Controls (n=12) 
Male sex, % 38% (3/8) 58% (7/12) 
Age, years (median, range) 37 (26-46) 60 (53-81) 
PSC duration, years (median, range) 4 (0-24) NA 
IBD, % 
Ulcerative colitis 
Mb Crohn 
Indeterminate colitis 
88% (7/8) 
86% (6/7) 
0% (0/7) 
14% (1/7) 
0% (0/12) 
Bilirubin, µmol/L (median, range) 11.5 (5-96) 8.5 (3-322) 
ALP, µkat/L (median, range) 
% >ULN 
3.9 (0.6-7.7) 
75% (6/8) 
1.6 (0.7-48.1) 
25% (3/12) 
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5 GENERAL DISCUSSION 
The general objective of this thesis was to explore different aspects on biliary strictures in 
PSC. So far, there is a paucity of knowledge regarding mechanisms involved in the chronic 
injury of the bile ducts in this disease. Once strictures are established in the large bile ducts, 
endoscopic treatment is often needed to relieve symptoms. However, there is a lack of 
evidence that endoscopic treatment will benefit the long-term outcome of patients. The 
downside of intervention, risks and adverse effects, is also insufficiently understood in PSC. 
Diagnosis of CCA in PSC also remains a challenge. Because of diagnostic methods with low 
accuracy, PSC patients are highly likely to be subjected to repeated invasive examinations in 
order to detect or rule out the presence of malignancy. Consequently, in the setting of PSC, 
we aimed to: Investigate and describe the risks of ERCP (Paper I). Evaluate the feasibility of 
SOC, an endoscopic technique for detecting CCA (Paper II). Evaluate the diagnostic 
performance of biliary brush cytology with stepwise use of FISH (Paper III). And finally, 
returning to the pathogenic aspect of the bile duct stricture, explore the potential role of 
MAIT cells in PSC and establish a novel method for assessment of MAIT cells in the biliary 
epithelium (Paper IV). 
5.1 PSC AND THE RISK OF ERCP-RELATED ADVERSE EVENTS  
In our study (Paper I), we used data from a quality register with prospectively registered data 
on procedure indications and maneuvers. We found that adverse events were frequent in the 
PSC group with 7.8% and 7.1% of PSC patients developing PEP and cholangitis respectively. 
In total, 18.4% of PSC patients had at least one adverse event registered. When comparing to 
non-PSC patients, this corresponds to a more than two-fold increase in risk for overall 
adverse events and PEP, and an almost fourfold increase in risk for cholangitis. Furthermore, 
we used logistic regression to develop predictive models for adverse events. In these models, 
PSC remained an independent risk factor for adverse events overall, PEP, cholangitis and 
extravasation of contrast. 
Previous studies examining the risk of adverse events following ERCP in PSC has reported a 
wide range of complications rates, 1.8%-17% (149, 154, 156, 166-170, 218-220). Although 
not consistent, the majority of studies have found a higher risk of cholangitis (0.6%-8%) and 
PEP (1.2%-7%) in PSC than in other patient groups (162). The reason for the wide range of 
reported frequencies of adverse events is not known. However, most studies are retrospective 
series evaluating stricture treatment. This might, for example, introduce selection bias since a 
prerequisite of inclusion would be successful cannulation thereby excluding patients with 
failed cannulation. Information bias, with unplanned data collection, is also a known 
drawback of the retrospective design. The small size of study cohorts is also a limitation in 
many studies. Furthermore, predisposing patient factors for adverse events and their relation 
to procedural risk factors (e.g. difficult cannulation and precut sphincterotomy) are only 
studied to a limited extent in PSC. 
. 
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5.1.1 Post-ERCP pancreatitis in PSC 
Risk factors for PEP have been identified by several studies (162-165, 208). Patient related 
factors include young age, female sex and the presence of a previous sphincterotomy. It is 
difficult to determine how these general factors affect the risk in PSC on a group-level. In our 
study, we found PSC patients more likely to be male, younger and a previous sphincterotomy 
was prevalent in 18% of PSC patients compared to 8% in the non-PSC group. Procedure 
related factors such as difficult cannulation (prolonged papilla contact, precut-
sphincterotomy), guide-wire cannulation of the pancreatic duct, sphincterotomy, 
cholangioscopy and therapeutic procedures (dilatation, stenting) are also associated with 
increased of PEP. These risk factors for PEP were mainly confirmed by our data. The 
distribution of procedure-related factors between PSC and non-PSC patients was unequal. For 
example sphincterotomy and stenting were more common interventions in non-PSC patients 
but other procedures such as biliary brushing and balloon dilatation were more likely to be 
performed in the PSC group. However, when adjusting for known risk factors, PSC remained 
as an independent risk factor for PEP in the predictive model, aOR 2.02 (95% CI 1.41-2.88).  
The high frequency of PEP in PSC (7.8%) in our study is in line data from a large 
retrospective patient series from Finland by Ismail et al, including 441 ERCP-procedures in 
PSC patients, in which the risk of PEP was 7.0% (168). Several risk factors for PEP in PSC 
were identified in this study. Female sex and a guide wire in the pancreatic duct were 
associated with a higher risk of PEP (OR 2.6 and OR 8.2 respectively). Interestingly a 
previous biliary sphincterotomy was shown to be a protective factor (OR 0.28). This was also 
suggested by data in our study where all cases of PEP in the PSC-group had a naïve papilla 
(n=26). We however deemed the PSC group to small to allow for subgroup-analysis of risk 
factors. 
The reason why PSC patients seem to have a high risk of PEP can be discussed. The notion 
that PSC patients are predisposed to difficult cannulation is to some extent supported by the 
study by Ismail. Despite that 37.8% of all procedures were done in patients with a previous 
sphincterotomy, access techniques such as pancreatic sphincterotomy and pre-cut 
sphincterotomy were used to a large extent (11.8% and 2.5%). Unfortunately, factors 
concerning cannulation difficulties were not registered in the national registry GallRiks 
between 2007 and 2009 and therefore not possible to assess in our study. Intriguingly, PSC 
seems to affect the pancreatic duct in some patients (221, 222). Sclerotic disease and early 
signs of pancreatic changes associated with extrahepatic bile duct sclerosis can be detected by 
MRI in a large proportion of patients with PSC (24%) (222). Hypothetically, the vulnerability 
of the pancreas may therefore be increased due to chronic inflammation and the response to 
injury more pronounced than in patients with a normal pancreas. 
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5.1.2 Post-ERCP cholangitis in PSC 
The high risk of cholangitis after ERCP in PSC found in our study has previously been 
reported in several studies (149, 166, 167, 169, 219, 220). Bangarulingam et al compared the 
risk of adverse events in PSC (n=168) and non-PSC (n=981). Despite the use of prophylactic 
antibiotics, the incidence of cholangitis was significantly higher among PSC patients (4% vs. 
0.2%) (166). This increased risk is likely related to inherent conditions of PSC with multiple 
strictures and impaired biliary drainage. Instrumentation then further facilitates colonization 
of gut flora with subsequent cholangitis. The registered use of prophylactic antibiotics among 
PSC patients in our cohort was surprisingly low, only 49%, despite the known risks in this 
patient group. However, we believe that this finding may reflect underreporting and/or 
inconsistency in the registry and a subgroup analysis did not suggest any association between 
prophylactic antibiotics and cholangitis in PSC patients. 
5.1.3 Extravasation of contrast 
The risk for extravasation of contrast was increased in PSC patients and occurred in 5.7% 
patients. Extravasation of contrast during ERCP is in most cases caused by a guide-wire 
perforation of the bile duct (223). This is a benign and self-limiting event in general (223). 
Moderate to severe perforations on the other hand are separately registered in GallRiks and 
only occurred in one PSC patient (0.7%). The increased risk for extravasation of contrast in 
PSC is likely caused by the strictured and narrow bile ducts that make navigation of the guide 
wire more difficult. The clinical impact of this risk is uncertain. Wire perforations are usually 
not associated with severe symptoms or outcome but may interfere with ERCP procedure and 
lead to premature termination and, in some cases, stenting of the affected bile duct. This 
would in turn generate prolonged hospital stay and a further need of ERCPs.  
5.1.4 Strengths and limitations 
A major strength of this study is the prospectively collected data registered in GallRiks. The 
use of appointed coordinators and validation of the registry further improves quality of data, 
allowing for a large number of variables with high reliability. In this study, we also validated 
that the indication “PSC or suspicion of PSC” actually represented a diagnosis of PSC. 
Nevertheless, misclassification in the opposite direction was not addressed in our validation. 
Most likely some PSC patients have been categorized as non-PSC patients with indications 
such as obstructive jaundice or malignancy. The effect of this is however expected to be 
small, diluted by the size of the control cohort.  
PEP prophylaxis includes the use of rectal non-steroidal anti-inflammatory drugs (NSAIDs) 
and pancreatic stent placement (224). A limitation in our study was that the use of prevention 
strategies for PEP was not registered in GallRiks during the period 2007-2009. The impact of 
these measures has not specifically been assessed in PSC. Therefore, information on its use 
would have had additional value in this aspect. 
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5.2 DETECTING MALIGNANCY IN PSC 
Diagnosing early CCA by non-invasive techniques generally lacks specificity. Bile duct 
sampling by ERCP has the ability to provide important diagnostic information in PSC 
patients with suspected features of biliary malignancy such as clinical deterioration, elevated 
levels of CA 19-9 or suspicious strictures seen on imaging (47). In two studies we evaluated 
two different invasive diagnostic methods for the detection CCA in PSC (Paper II and III). In 
our prospective study of the clinical utility of SOC in PSC we evaluated technical feasibility, 
safety and diagnostic accuracy of targeted sampling (Paper II). We found that SOC could 
successfully be used in almost all (96%) included patients. In a retrospective diagnostic study, 
we evaluated the diagnostic performance of biliary brush cytology with sequential use FISH 
in equivocal cases (Paper III). We show that the diagnostic algorithm used had higher 
sensitivity (80%) than expected from routine cytology alone with an acceptable level of 
specificity (96%). Diagnostic accuracy (i.e. proportion of correctly diagnosed patients) was 
95% (197/208). 
5.2.1 SOC 
5.2.1.1 Technical feasibility 
The main possible advantage of SOC in PSC is that it offers direct visualization of the bile 
duct and enables sampling of suspicious strictures with targeted biopsies. SOC has been 
evaluated in several case series of non-PSC patients with indeterminate strictures (205, 206, 
225, 226). In comparison to brush cytology alone SOC with targeted biopsies is reported to 
increase the sensitivity (77%-82%) for detecting biliary malignancy (206, 225). The benefit 
of SOC in PSC is however not obvious for two main reasons. First, the altered morphology of 
the biliary tree with narrow ducts makes cannulation with the cholangioscope technically 
difficult (227) and the use of cholangioscopy increase the risks of adverse events (228). 
Second, the inflammatory and fibrotic bile ducts of PSC patients make it difficult to visually 
discriminate them from malignant lesions (229). Despite these obstacles, we showed that 
SOC was technically feasible with successful cannulation, adequate visualization and 
sampling of suspected lesions in 45/47 (96%) of patients. This is line with what Siiki et al 
reported in a smaller series of PSC patients (n=11) evaluated with SOC in which all 
examinations were technically successful (230).  
5.2.1.2 Sampling adequacy and diagnostic accuracy 
A limitation of SOC is the small amount of tissue acquired by the mini-forceps used for 
sampling (225). Although not defined in the study protocol, at least four separate biopsies 
were taken per evaluated stricture. This rendered a sampling adequacy of 95% (21/22). 
In general, the visual quality of SOC did not allow for discrimination between inflammation 
and premalignant lesions. Only one patient with malignancy was identified by endoscopic 
appearance. In all strictures categorized as suspicious for cancer (3/3) by macroscopic 
features, sampling results revealed no malignancy or dysplastic changes. In studies evaluating 
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SOC in other patient categories, visual assessment as been reported to be the most sensitive 
method to detect CCA (sensitivity 95%, specificity 75%) (206). In our series we used the first 
generation fiber-optic Spyglass system with image quality often suboptimal and easily 
impaired by mucus, blood or PSC alterations in the bile duct. Since the study period, a newer 
system has been developed with a digital image solution (SpyGlass DS; Boston Scientific) 
and higher image quality. However, even with instruments with superior image quality to the 
first generation Spyglass system the detection of dysplasia seems difficult in PSC. In a case-
series of 30 PSC patients, high-resolution per-oral video cholangioscopy with narrow-band 
imaging (NBI) was evaluated for detection of CCA and dysplasia (231). With this method, 
CCA and tumor margins could be detected, but visual assessment of the bile duct mucosa did 
not increase the detection of dysplasia. 
Three patients were diagnosed with CCA during follow-up. The first patient was diagnosed at 
inclusion and had endoscopic appearance, biopsies and brush cytology results positive for 
malignancy. The two remaining patients were diagnosed after 17 months with and 
intrahepatic CCA and after 35 months with a hilar CCA. We included these patients when 
evaluating diagnostic accuracy for SOC-guided sampling, although this approach can be 
criticized. Sensitivity, specificity, PPV, NPV and accuracy were 33% (95% CI 1-91%), 100% 
(95% CI 92-100%), 100% (95% CI, 3-100%), 95% (95% CI 85-99%) and 96% (95% CI 85-
100%). The few number of events however precludes any firm conclusions based on these 
findings. 
5.2.1.3 Adverse events 
The frequency of previously reported ERCP-related adverse events in PSC vary considerably 
(232). We found a relatively high risk of procedure-related adverse events in this patient 
series. In 7/47 patients (14%) complications occurred. In six cases, the adverse events were 
classified as mild with little impact or prolonged hospital admission no longer than 3 days. 
One case of cholangitis was classified as moderate. Although the few number of patients 
limits conclusions we argue that risks should be carefully weighed when evaluating patients 
with this invasive technique.  
5.2.1.4 Additional technical value 
We also tried to evaluate possible technical advantages associated with SOC. First, one 
possible advantage is guidance through visualization of the bile duct to pass the guide-wire 
through narrow strictures. This was found to be the case in 4/45 (9%) patients. Second, it has 
previously been described that SOC increases the detection and subsequent removal of bile 
duct stones in PSC (229). In 12/45 (27%) patients in our series biliary stones were detected 
and removed in 11 of these cases. The clinical implication of these possible advantages 
remains to be determined. To access and sample suspicious lesions in PSC patients can be 
technically demanding. SOC could, in this setting, offer a technique to reach and sample 
otherwise inaccessible strictures when necessary. Whether increased detection and removal 
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of biliary stones in PSC is beneficial or not is not known. These hypothetical advantages 
deserve attention in future studies on the subject. 
5.2.1.5 Strengths and Limitations 
The main strength of this study is the prospective design that allows for a robust evaluation of 
success rates and adverse events. However, given the small sample size results should be 
interpreted with caution. Also the limited number of patients with malignancy precludes any 
meaningful evaluation of the diagnostic accuracy of SOC with targeted biopsies in this 
patient-series.  
5.2.2 Biliary brush cytology and FISH 
In this retrospective study (Paper III), we evaluated the diagnostic performance of brush 
cytology with sequential use of FISH in equivocal cases for detection of CCA and biliary 
dysplasia in patients with PSC. We showed that a correct diagnosis could be made in 95% 
(197/208) of cases in this relatively unselected cohort of PSC patients with a clinical 
indication for ERCP. We also demonstrated that sequential use of FISH in equivocal cases 
shows a higher sensitivity (80%), than previously reported results of routine cytology, while 
an acceptable level of specificity (96%) was maintained (192). Furthermore, we found that 
FISH was highly sensitive (100%) for the detection of CCA in PSC patients with no evidence 
of malignancy on prior imaging and that false positive results correlated to biliary dysplasia 
in explanted livers. 
5.2.2.1 The positive predictive value of FISH 
We believe that the present study, complements the current data on the value of FISH 
analysis in PSC. Previous studies in the field have focused on evaluation of the risk for 
development of CCA in patients with a positive FISH analysis using a longer follow-up time. 
In one study of 102 PSC patients with no definite signs of CCA on imaging and equivocal 
cytology results, 29% was diagnosed with CCA within 2 years. The risk of CCA was 
increased more than eight times in cases with a positive FISH (HR 8.70 (95% CI 3.79–
19.99). In another study of 235 PSC patients, in which patients were followed up to 34 
months, the sensitivity of FISH for detection of later CCA development was shown to be 
46% and the specificity 88%. At Karolinska University Hospital, as well as in all Nordic liver 
transplant centers, biliary dysplasia is an indication for LTx in PSC. This transplant setting, in 
which patients with HGD are offered LTx, has allowed us to evaluate the diagnostic accuracy 
of biliary brush cytology with FISH in a relatively short perspective (within 12 months). We 
therefore chose a diagnostic study design in contrast with multiple previous studies 
evaluating FISH as a risk factor for developing CCA at long-term follow-up (196, 199, 201, 
202, 233). The diagnostic perspective in the present study gives further guidance how to 
interpret brush cytology in PSC patients.  
As anticipated, applying FISH in equivocal cases of routine brush cytology showed a higher 
sensitivity than previously published results of routine cytology (192), but at the cost of 
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decreased specificity for identifying established CCA. The PPV of a brush positive for either 
malignant cells or FISH was 60% in our study. This may in part be explained by previously 
published results showing that the genetic alterations detected by FISH are not specific for 
CCA but also present in preneoplastic changes. In a study of by DeHaan et al., biliary 
dysplasia in liver resections and explanted livers from PSC patients, demonstrated either 
FISH polysomy or homozygous 9p21 loss in all specimens (5/5) (234). Thus, it is likely that, 
at least partly, the positive findings of FISH in this study are explained by biliary dysplasia.  
When including HGD and both HGD and LGD as positive endpoints, PPV increased from 
60% for CCA only to 75% and 90%. Although the number of patients with dysplasia was low 
in the present study, all patients with HGD in explanted livers (3/3) had a brush cytology 
positive for FISH. Previously published data strongly supports that CCA develops in areas 
with dysplastic lesions in PSC, but the time and course of this process is not known (186). In 
addition, PSC patients positive for FISH polysomy, either in equivocal cytology or in 
multifocal or serial samples, are highly likely to develop CCA (196, 199, 201, 202). 
Chromosomal aberrations detected by FISH may itself indicate a higher risk for malignant 
transformation than histologically identified dysplasia. Although probable, it is, however, 
difficult to obtain figures supporting this assumption. Risk stratification of PSC patients 
according to FISH status might be a rational approach although we note that cancer was 
already prevalent in 58% of patients with equivocal brush cytology with positive FISH and a 
negative imaging (i.e. no definite malignancy).  
5.2.2.2 The negative predictive value of FISH 
A high NPV of 98% was reached using FISH in equivocal cases. In clinical practise, it is 
important to rule out the presence of CCA or HGD in a significant stricture seen at imaging.  
Our study population includes referral cases from other regions but most patients were 
included from our primary catchment area. This is reflected by the relatively low prevalence 
of CCA of 7%, and that only two patients had obvious signs of malignancy prior to brushing. 
Thus, a high NPV for the entire group of patients with clinical indication for ERCP is 
expected. However, even in patients with equivocal cytology a negative FISH result was 
highly accurate for ruling out malignancy at 12 months (NPV 100%). 
5.2.2.3 Strengths and limitations 
Strengths of this study include the relatively large size of the study cohort covering all PSC 
patients who underwent biliary brushings during the study period. Also, almost all identified 
patients had a complete follow-up and could be included in the final analysis thus limiting 
selection bias. There are, however, several limitations to our study, mainly due to the 
retrospective design with its inherent flaws. During the study period, FISH results have been 
used in clinical decision-making, introducing verification bias, meaning that patients were not 
randomly allocated to interventions (e.g. LTx, surgical resection), which are of importance 
for the final diagnosis. The consequence of this partial verification would be a potential 
overestimation of the prevalence of early CCA and biliary dysplasia in patients with a 
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positive FISH. Consequently, an overestimation of the NPV would then likewise be the case 
since patients with a negative FISH finding might harbor undetected early CCA or HGD. 
Furthermore, since the results of biliary brush cytology are available to the pathologist 
interpreting the final histopathology (e.g. from an explanted liver) diagnostic review bias 
might also have affected the results in a similar fashion. 
The choice of using only the index brush cytology result for calculation of the diagnostic 
accuracy is also debatable. The main limitation of this approach is that it also includes false 
negative results by sampling error, which is separate from the cytological diagnostic method 
itself. However, when we included results from repeated brushings the values for diagnostic 
accuracy did not change, although the number of cytology results with insufficient material 
did decrease (data not shown). 
The follow-up time was restricted to 12 months. We argue that this approach is relevant for 
evaluation of FISH as a diagnostic test since a reduced follow-up time reflects the prevalence 
of CCA or dysplasia at the time of first brushing rather than progression of preneoplastic 
changes that might occur over time. Finally, there were a limited number of patients with 
CCA in our cohort, despite having a relative large overall sample size. Our results should 
therefore be interpreted with caution. 
5.2.3 Present and future perspectives 
Detection of malignant and premalignant lesions in the bile ducts of PSC patients remains a 
challenge. The use of FISH and SOC both provide additional diagnostic means that together 
and in combination with other techniques such as imaging can improve diagnostics. Studies 
with the aim to investigate biomarkers in serum and bile are ongoing and would further have 
the potential to improve diagnostics. However, the rarity of PSC makes it difficult to evaluate 
such markers and robust diagnostic methods cannot be expected in the near future. 
5.3  MAIT CELLS IN PSC 
In Paper IV we performed a detailed characterization of peripheral blood MAIT cells in PSC. 
We observed reduced MAIT cell frequencies, phenotypic changes consistent with activation 
and possibly exhaustion, as well as impaired functional responses upon MR-1 dependent and 
independent stimulation. Furthermore, MAIT cells were found to be enriched in the biliary 
epithelium as compared to peripheral blood, and comparable to MAIT cell frequencies and 
numbers of non-PSC controls. This suggests that MAIT cells are retained in the compartment 
affected by chronic inflammation in PSC. 
5.3.1 Influence of inflammation and liver disease on peripheral MAIT cells 
MAIT cells are enriched in the healthy human liver (217) and have been studied to some 
extent in different liver diseases. In chronic hepatitis C virus infection (235) as well as in 
alcoholic liver disease (236) MAIT cells are lost from circulation and present with functional 
impairment. These findings are in line with our observations in patients with PSC. Thus, it 
appears that a common profile of the MAIT cell population in chronic liver inflammation is a 
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reduction in frequency combined with functional impairment. MAIT cell depletion and 
dysfunction in peripheral blood have also been described for several other human diseases 
where the immune system is chronically activated. Conditions affecting the MAIT cell 
population include both single organs, for example multiple sclerosis (237), rheumatoid 
arthritis (238), and IBD (239), as well as more general systemic inflammatory settings, such 
as chronic HIV-infection (240, 241), systemic lupus erythematosus (242), and in metabolic 
inflammation during obesity and type 2 diabetes (243). It is currently unknown whether a 
common underlying mechanism is accountable for MAIT cell loss and functional impairment 
in these conditions or whether specific mechanisms exist in each disease. 
One hypothesis that could explain the abnormal MAIT cell population is loss of gut integrity 
and subsequent microbial translocation. Many of the above-described conditions associate 
with a “leaky” gut such as chronic HCV infection (244), alcoholic liver disease (245), and 
chronic HIV infection (246). Increased presence of intestinal bacteria and bacterial antigens 
and metabolites would then lead to MAIT cell activation, and over time MAIT cell 
exhaustion and apoptosis as a consequence of the prolonged insult. Evidence for such a 
mechanism has been presented both for patients with chronic HIV infection as well as in 
alcoholic liver disease (245, 246). In the case of PSC, and except for the actual inflammation 
in the liver that could promote gut leakiness, many patients also have concomitant IBD 
further exacerbating the microbial translocation. Of note, we observed no significant 
differences regarding the MAIT cell loss and functional impairment in patients with PSC and 
IBD, or in patients with PSC and IBD only. The exact process by which MAIT cells become 
activated (and exhausted) and eventually die still remains unknown. However, it is interesting 
to note that removal of the chronic insult, in the case of chronic HCV via treatment with 
direct acting antivirals (235), does not readily lead to a reinvigoration, suggesting that the 
insult inflicted on the MAIT cell population during chronic inflammation might be long-
lasting and perhaps irreversible. 
A recent report investigated MAIT cells in humans affected by different autoimmune liver 
diseases, including PSC (247). Our findings are in line with this report including loss of 
MAIT cells from circulation, an activated (and possibly exhausted) phenotype, as well as a 
functional impairment. Interestingly, the authors further suggested that MAIT cells could 
contribute to liver fibrosis development via production of IL-17 and subsequent hepatic 
stellate cell (HSC) activation (247). PSC-patients are known to have increased CD4 T cell 
Th17-responses (73). However, in this regard, we could not detect increased MAIT cell IL-17 
levels, neither upon E.coli nor cytokine stimulation. 
5.3.2 MAIT cells in the biliary epithelium 
PSC is a disease of extra- and intrahepatic bile ducts. Although work in previous studies have 
tried to localize MAIT cells within the liver parenchyma, and have reported that the cells are 
present in portal tracts surrounding bile ducts (92, 247), it has been challenging to specifically 
assess MAIT cells in bile ducts. To overcome this, we established a novel method allowing 
sampling of bile duct tissue during ERCP procedures for subsequent MAIT cell analysis. In 
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line with the fact that MAIT cells are accumulated in peripheral organs, such as the liver as 
well as at mucosal barriers, we here report that MAIT cells are enriched four-fold in bile 
ducts as compared to peripheral blood. Intriguingly, and in contrast to the circulating MAIT 
cell compartment, we also observed retained levels of MAIT cells in bile ducts from PSC 
patients as compared to controls. The specific role for MAIT cells in the pathogenesis of PSC 
is currently unclear. However, the possibility to assess bile duct MAIT cells will allow for 
future studies on this topic. The recent development of SOC with high quality visualization is 
also interesting in this aspect (248). The possibility to visually identify bile ducts affected by 
inflammation may allow for a more precise sampling and detailed assessment of the 
inflammatory process. 
5.3.3 Limitations 
Several limitations of our study have to be considered. First, we used a cross-sectional cohort 
with sampling at one time-point only. Second, we did not detect clear correlations between 
MAIT cells and parameters of disease severity. One reason for this might be that our cohort 
consisted of patients with relatively mild disease. Future studies should include larger patient 
populations and longitudinal sampling for identification of correlates between immune 
system function and PSC disease activity and progression. Third, and on a more 
technological level, we identified MAIT cells with flow cytometry using the combination of 
antibodies against the TCR Vα7.2 chain and CD161. Although it would have been more 
advantageous to instead use an MR1-tetramer, this tool was not commercially available at the 
time of our study. To account for this, we restricted our analysis to CD8+ or CD4-CD8- 
Vα7.2+CD161+ T cells, since CD4+ Vα7.2+CD161+ T cells have been shown to contain 
more “non-MAIT” cells (249, 250). 
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6  CONCLUSIONS 
PSC is associated with a high risk of ERCP-related adverse events (Paper I) 
PSC is an independent risk factor for ERCP-related adverse events overall and for cholangitis 
and pancreatitis (Paper I) 
Single-operator cholangioscopy is technically feasible in PSC (Paper II) 
The use of single-operator cholangioscopy to improve sensitivity of bile duct sampling for 
CCA in PSC could not be sufficiently evaluated in this thesis and further studies are needed 
to assess this. (Paper II)  
Biliary brush cytology with use of FISH in equivocal cytology cases has a high diagnostic 
accuracy in PSC (Paper III) 
A negative FISH analysis for aneuploidy in equivocal cytology cases has a very high negative 
predictive value for cholangiocarcinoma (Paper III) 
PSC is associated with an altered MAIT cell population in peripheral blood with reduced 
frequencies, an activated phenotype and impaired function (Paper IV) 
Alterations of the MAIT cell population in PSC are similar do those seen in patients with 
ulcerative colitis and primary biliary cholangitis (Paper IV) 
Using biliary brush samples to assess MAIT cells in the biliary epithelium is feasible (Paper 
IV) 
MAIT cells are retained in the biliary epithelium in PSC (Paper IV) 
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Primär skleroserande kolangit (PSC) är en ovanlig men allvarlig leversjukdom med dålig 
prognos kopplad till en stor risk för utveckling av både levercirros (skrumplever) och 
gallgångscancer. Det som kännetecknar sjukdomen är en kronisk inflammation i gallgångarna 
i och utanför levern. Inflammationen leder till ärrbildning och förträngningar (strikturer) som 
förhindrar flödet av galla. Detta leder till utveckling av levercirros och sviktande funktion hos 
levern. PSC är starkt kopplat till inflammatorisk tarmsjukdom som finns hos 80 % av 
patienterna. Sjukdomen är ovanlig, i Norden uppskattas den förekomma hos 10 individer per 
100 000 invånare. Det som har kommit att radikalt förändra prognosen vid PSC är 
utvecklingen av levertransplantation som behandling under början av 1980-talet. Innan dess 
dog en stor andel patienterna av leversvikt och andra komplikationer. Sjukdomsförloppet 
varierar stort men efter ungefär 20 år är hälften av patienterna antingen transplanterade eller 
döda. Trots att PSC är ovanligt är det den vanligaste orsaken till levertransplantation i Sverige 
och Norden. Det finns en starkt ökad risk för både tjocktarmscancer och cancer i gallgångarna 
(kolangiocarcinom) vid PSC. Ungefär 10 % av alla patienter utvecklar kolangiocarcinom och 
denna cancerform har mycket dålig prognos om man inte kan ge botande behandling i tidigt 
skede.  
Under de senaste decennierna har forskning gett en ökad förståelse för PSC. Kartläggning av 
genetiska faktorer har visat en stark koppling mellan sjukdomen och gener inblandade i 
immunförsvarets utveckling och reglering. Samtidigt finns en stark koppling till andra så 
kallade autoimmuna sjukdomar som typ 1 diabetes och glutenintolerans. Även om PSC är 
ovanlig så verkar den öka i befolkningen över tid, precis som andra autoimmuna sjukdomar. 
Orsaken till det är inte känd men olika teorier finns om hur miljöfaktorer som ökad hygien 
(minskad exponering för mikroorganismer) och förändrad kost kan påverka risken. Nya 
röntgentekniker, förförallt magnetkameraundersökning (MR), har också gjort det lättare att 
hitta och diagnosticera patienter. Trots framsteg finns fortfarande ingen medicinsk behandling 
som påverkar sjukdomsförloppet. Inte heller har vi någon klar bild av hur sjukdomen 
uppkommer. Gallgångscancer har fortfarande stor betydelse för den ökade dödligheten vid 
PSC. De diagnostiska metoder som används för att hitta cancern har i regel dålig träffsäkerhet 
och osäkra resultat i tidigt skede.  
I denna avhandling har vi med utgångspunkt från gallvägsstrikturer vid PSC dels undersökt 
sjukdomsmekanismer dels studerat diagnostiska metoder för cancer i gallvägarna. 
En nyckelmetod för att undersöka gallgångarna vid PSC är endoskopisk retrograd 
kolangiopankreatografi (ERCP). ERCP kombinerar ett videoinstrument (endoskop), som förs 
ner i tolvfingertarmen, med röntgenteknik där kontrast sprutas in i gallgången för att 
visualisera stenar, tumörer och andra förträngningar. Fördelen med ERCP är att man vid 
undersökningen också kan vidga strikturer samt ta vävnadsprover från misstänkta tumörer. 
Nackdelen är att det finns risk för komplikationer som kolangit (bakterieinfektion i 
gallvägarna) och pankreatit (inflammation i bukspottskörteln). I tre separata studier har vi 
utvärderat olika aspekter av denna undersökningsmetod. 
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I den första studien har vi kartlagt risken för komplikationer vid ERCP hos patienter med 
PSC. Vi utgick från ett svenskt nationellt kvalitetsregister, GallRiks, där nästan samtliga 
undersökningar som görs i Sverige registreras. Totalt 8932 individer varav 141 PSC-patienter 
ingick i studien. Vi fann att komplikationer vid ERCP var mer än dubbelt så vanligt hos 
patienter med PSC jämfört med andra patienter. Särskilt stor var risken för kolangit och 
pankreatit. 
Kolangioskopi är en endoskopisk metod för att titta in i gallgångarna och ta vävnadsprover 
från misstänkt cancer. I studie II kunde vi visa att kolangioskopi med vävnadsprover var 
tekniskt genomförbart vid PSC. Större studier behövs för att påvisa om metoden tillför nytta 
vid cancerdiagnostik i denna patientgrupp.  
Borstcytologi (cellprovtagning) är en annan metod för att påvisa cellförändringar och cancer i 
gallvägarna men resultaten är ofta svårtolkade och osäkra. I studie III utvärderade vi om 
denna metod kan förbättras genom att också analysera kromosomförändringar som kan finnas 
hos cancerceller. Vi kunde i denna studie visa att detta gav en ökad säkerhet i diagnostiken 
med en ökad känslighet för att upptäcka gallvägscancer. 
Så kallade mucosal associated invariant T-cells (MAIT-celler) är en grupp av immunceller 
som försvarar kroppen mot angrepp av mikroorganismer i framförallt slemhinnor. Dessa 
celler är i hög grad ansamlade också i levern men deras funktion där är i stora delar okänd. I 
den fjärde studien har vi undersökt och karaktäriserat MAIT-celler i blodet hos patienter med 
PSC och jämfört med andra patientgrupper (med inflammatorisk tarmsjukdom och annan 
kronisk leversjukdom) samt friska individer. Vi kunde i denna studie visa att MAIT-celler 
hos PSC patienter i hög grad skiljer sig från de som finns hos friska individer. I blod uppvisar 
dessa celler tecken på att vara aktiverade och ”utmattade”. Vi har också utvärderat MAIT-
cellers förmåga att döda infekterade celler och rekrytera andra delar av immunförsvaret. 
Dessa funktioner visade sig vara nedsatta vid PSC jämfört med friska individer. MAIT-
cellernas profil vid PSC (aktivering, utmattning och nedsatt funktion) är dock inte specifik för 
sjukdomen utan liknar den hos patienter med inflammatorisk tarmsjukdom eller annan 
leversjukdom. I denna studie utvecklade vi också en metod för att analysera MAIT-celler från 
cellprover tagna i gallvägarna. Vi fann att MAIT-celler är anrikade i denna del av kroppen 
jämfört med blod både vid PSC och hos andra patientgrupper. 
Sammanfattningsvis ger resultaten från denna avhandling insikt i flera viktiga aspekter av det 
kliniska omhändertagandet av patienter med PSC. Vi har visat att risken för komplikationer 
vid ERCP hos denna patientgrupp är stor. Vi visar också hur borstcytologi kan förbättras för 
mer exakt diagnostik av gallvägscancer. Vidare fann vi att kolangioskopi har en potentiell roll 
i denna diagnostik men för att påvisa nytta behövs större studier. Vi har också detaljerat 
beskrivit MAIT-celler vid PSC. Slutligen har vi med en nyutvecklad metod påvisat dessa 
celler i gallvägarna hos individer med och utan PSC. 
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